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Whitney Ann Bullock 
THE ROLE OF WNT SIGNALING IN BONE MECHANOTRANSDUCTION  
The aging US population is experiencing a growing incidence of osteoporosis, 
characterized by increased fracture risk and low bone mass. In skeletal tissue, canonical 
Wnt signaling is a critical regulator of bone mass, and dysregulation of the Wnt pathway 
has been implicated in numerous skeletal displasias. Some components of the Wnt 
signaling pathway have a clear role in bone homeostasis, particularly in the response of 
bone to altered mechanical environment. Other pathway components are more poorly 
defined. One important intracellular signal transduction node in the Wnt cascade is -
catenin, which modulates gene expression and cell-cell junctions, among other functions. 
During periods of disuse, -catenin is degraded, leading to inhibition of Wnt targets. 
Here, I characterize the role of -catenin in bone during a disuse challenge, using a 
genetic mouse model expressing an inducible constitively-active mutant form of -
catenin in the osteocyte population. I hypothesize that prevention of -catenin 
degradation during disuse will prevent the bone wasting effects of mechanodeprivation. 
As a second goal, I focus on upstream (membrane-bound) modulation of Wnt. Here, I 
investigate the low-density lipoprotein receptor-related receptor 4 (Lrp4), in the 
regulation of bone mass and mechanotransduction. I generated an Lrp4 knockin mouse 
model harboring a missense mutation found among human patients with abnormally high 
bone mass. I hypothesize that the mutation compromises sclerostin action on bone cells. 
Understanding how each of these components of the Wnt signaling pathway interact, may 
lead to novel therapeutic targets for treatment of bone diseases. 
Alexander Robling, PhD, Chair 
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Chapter 1: The Role of Wnt Signaling in Bone Mechanotransduction 
Osteoporosis—a disease characterized by low bone mass and increased fracture 
risk—is a growing problem among the aging US population [6, 7]. The prevalence of low 
bone mass, especially among post-menopausal women, highlights the need for therapies 
to increase bone mass. Each of the FDA-approved therapies for treating osteoporosis is 
associated with unwanted side effects (blood clots associated with SERM use, 
bisphosphonate storage in bone tissue associated with atypical fractures, cancer concerns 
with teriparatide, cardiovascular risk with sclerostin antibody), so understanding 
additional pathways that regulate bone mass could provide new potential drug targets that 
might have fewer side effects.  
The mechanical environment of bone tissue represents a key regulator in the 
maintenance of bone mass, and absence of mechanical stimulation (disuse) has profound 
bone wasting effects. Paralysis, long-term bed rest, and space flight all result in reduced 
mechanical stimulation and a reduction in bone mass, leading to increased risk of 
fracture. In the absence of a steady-state mechanical environment, osteoblast activity 
decreases, while bone resorption by osteoclasts increases. Osteocytes are the 
mechanosensors in the skeletal system, and they regulate osteoblast and osteoclast 
differentiation and activity through multiple mechanisms (Figure 1).  The altered 
mechanical environment experienced by the osteocyte induces biochemical changes in 
the local cell populations that ultimately facilitate bone adaptation.  These changes–
collectively known as mechanotransduction—involve activation and inhibition of 
numerous pathways that coordinate to achieve an adapted structure.   
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Mechanotransduction in bone: concepts and mechanisms 
Detection of mechanical stimuli, and transformation of mechanical signals into 
biochemical responses, is facilitated by the vast network of cytoplasmic processes that 
extend from the osteocyte cell body throughout the lacuna-canalicular network in 
mineralized bone. Cell surface molecules and structures (integrins/cadherins, ion 
channels, G-protein coupled receptors, primary cilia) and intracellular signaling pathways 
(Wnt/β-catenin, mitogen-activated protein kinases, tyrosine kinases, cGMP/cAMP 
pathways) detect and transduce mechanical signals from osteocyte “sensor cells” into 
altered bone remodeling by “effector cells” (osteoblasts, osteoclasts, bone lining, Figure 
1). Several fundamental processes that control skeletal adaptation to mechanical loading 
have been identified and integrated with signaling pathways, leading to a better 
understanding of bone tissue engineering and physiology [8], creating new opportunities 
for clinical/pharmaceutical and exercise strategies to promote skeletal health. 
Cells within bone detect, coordinate and mediate mechanical loading on the 
skeleton. Key questions include 1) how the cells embedded within and on the surfaces of 
bone sense and respond to externally applied mechanical loads, 2) whether the 
mechanical stimulus is direct tissue strain from loading/bending of bone, or an indirect 
consequence of the load (i.e., load-induced fluid flow over the surfaces of bone cells), 
and 3) how cells translate a mechanical signal detected at the cell surface into an 
appropriate sequence of biochemical changes inside the cell that results in a coordinated 
anabolic or catabolic response. 
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The cells most likely to function as the “mechanosensors” in bone are the 
osteocytes. Intuitive considerations and abundant experimental evidence supports the 
assignment of osteocytes as the bone cells most directly responsible for detecting 
mechanical signals and orchestrating the skeletal response to those signals. Osteocytes 
within individual lacunae are perfectly positioned as mechanosensors since they are 
distributed uniformly throughout cortical and trabecular bone and are connected by 
system of canals. This allows osteocytes to function in a network capable of sensing load-
induced signals virtually anywhere in the skeleton.  Long cytoplasmic processes 
(~50/cell) interconnect the cells comprising this vast network to each other via gap 
junctions, which facilitate cell-cell communication. However, these same properties make 
osteocytes unlikely candidates for effector cells that directly add or remove bone from 
bone surfaces. Although osteocytes can mediate localized removal of mineralized matrix 
and calcium release from their own lacuna, this localized activity has little effect on the 
size, shape, and structural properties of the skeleton. Osteoblasts, bone lining cells and 
Figure 1. The bone microenvironment. The bone microenvironment is a complex system 
consisting of bone-forming osteoblasts, bone-resorbing osteoclasts and mechanosensitive 
osteocytes. These cells coordinate bone homeostasis through complex signaling mechanisms. 
Figure from [4]. 
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osteoclasts function as the “effector” cells that add or remove bone under the direction of 
signals from the osteocyte network.  
To understand how physical stimuli affect bone cells, I must consider the vastly 
different microenvironments that different bone cells inhabit.  Stromal (MSC) cells for 
instance reside in the bone marrow space of long bones and vertebrae, have minimal 
extracellular space surrounding them, and no rigid substrate to contact. In contrast, 
osteoblasts, osteocytes and bone lining cells attached to the hard surfaces of bone, 
experience higher surface strains as well as movement of fluid over their surfaces.  The 
physical environment of the osteocyte is truly unique.  Osteocytes encase themselves in 
mineralized matrix. Importantly, they create a small fluid filled form-fitting cavity within 
their lacuna and extend cell processes that course through the matrix in narrow canaliculi. 
The canaliculi average about 260 nm in diameter and the space between the projection 
membrane and the canalicular wall is very narrow (~80 nm), creating the potential for 
high velocity fluid movement driven by load-induced pressures or matrix strains. Finite 
element modeling indicates that typical macroscopic level strains on bone can result in 
greatly amplified strains at the microscopic level of the perilacunar space [9]. For years 
the strongest argument favoring the osteocyte network as the primary mechanosensory 
system in bone was based on these characteristics. Fortunately, experimental support for 
this hypothesis now exists. Osteocytes are more sensitive and respond differently to fluid 
flow-induced shear stress compared to osteoblasts in vitro [10, 11], and experiments in 
mice demonstrated a key functional role for osteocytes in detecting disruptions to normal 
mechanical loading. A transgenic mouse was created that enabled efficient ablation of the 
majority of osteocytes without affecting osteoblasts and osteoclasts [12]. These mice 
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were protected from disuse-induced bone loss, demonstrating a key role for the osteocyte 
network in sensing the loss of normal skeletal loading. Although inflammatory effects, 
including enhance osteoclast formation, following induction of such massive osteocyte 
death, complicate this analysis [13], there is an overwhelming consensus that osteocytes 
are the primary mechanosensory cells in bone. 
Fluid flow and tissue strain in bone  
There is a strong argument in favor of mechanically generated oscillatory fluid movement 
within the lacunocanalicular network being the most physiologically relevant cell level 
mechanical stimulus. Although tissue strains produced by bending the bone matrix can 
induce mechanical signals detected by osteocytes, the vast array of cytoplasmic processes 
of the osteocyte positions these cells to sense fluid flow. Indeed, the ability of the 
extracellular domains of integrins expressed on the long cytoplasmic osteocyte processes 
appear to be capable of “amplifying” relatively small fluid forces into disproportionally 
large biochemical responses inside osteocytes [14].  Osteocytes are physically connected 
to the extracellular glycocalyx within the canalicular walls via integrin heterodimers. 
Subtle changes in the conformation of integrin extracellular domains are transduced to 
the cell interior via short cytoplasmic tails. Growing evidence suggests that integrin-
associated signaling and cytoskeletal proteins transmit mechanical signals directly to the 
nucleus to alter gene expression.  
Experimental limitations must be considered when evaluating mechanical sensory 
mechanisms and the relative contributions of fluid flow and substrate strain in osteocytes. 
First, most published studies are based on in vitro cell culture experiments using 
osteoblasts or osteocyte-like cell lines; since primary osteocytes are difficult to isolate in 
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sufficient numbers for experimental study. Determining the contribution of tissue level 
strains in bone as biologically relevant osteocyte stimuli is also challenging [15]. 
Measurements of tissue strain collected on the periosteal surface of long bones indicate 
that the peak strain generated during strenuous activity is approximately 3,000 µε.  When 
bone cells grown on 2-dimensional culture substrates are exposed to 3,000 µε no 
detectable response can be measured. In fact, greater than 10,000 µε must be applied 
before most in vitro models will yield a measurable response.  Application of 10,000 µε 
is beyond the yield point of bone in vivo and fracture occurs before sufficient tissue strain 
stimulates bone cells. However, application of loads generating ~2000 µε on a bone’s 
surface may generate local strains up to 30,000 µε on the osteocyte lacunar wall. This 
Figure 2. Osteocytes are the mechanosensor of bone. Mechanotransduction in osteocytes is 
dependant on fluid flow in the osteocyte canalucilar network. Fluid flow during mechanical 
loading in bone results in osteocyte-osteocyte, osteocyte-osteoblast and MSC paracrine signaling. 
Figure from [2]. 
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difference in macro vs micro level strain is possibly a consequence of stress-
concentrating effects of the voids produced by osteocyte lacunae [14]. 
Much less controversial is the impact of shear stress generated as extracellular 
fluid moves across osteocyte surfaces from areas of higher to lower pressure when a long 
bone is bent during loading (Figure 2). Fluid shear stress potently stimulates osteocytes 
and other bone cells in vitro. Enhanced transport of growth factors and nutrients, removal 
of waste products of metabolism (chemotransport), and generation of electrical streaming 
potentials may also affect osteocyte responses to fluid flow. Chemotransport also affects 
the response of bone cells to fluid flow independent of mechanical signal transduction 
[16].  
An intriguing model for osteocyte mechanotransduction has been developed by 
the Schaffler and Weinbaum laboratories [14] based upon microscopic level studies of 
osteocytes in bone piece. Their model considers the observation that the cytoplasmic 
processes appear to be suspended from the canalicular wall via integrin adhesion 
complexes attached to tethering structures made from the glycocalyx . They suggest that 
fluid flow through the space between the membrane and the glycocalyx wall “deflects” 
these tethering structures, resulting in deformation referred to as “hoop strain” 
Deformation of these tethering structure results in a strain amplification that is radial, like 
a hoop. As a result of this amplification, estimates suggest that local cell membrane 
strains may be 10-100-fold higher than grossly measured tissue strains.  
Molecular basis for mechanotransduction in bone 
Having considered both the physical environment and the mechanical forces to which 
osteocytes are exposed, how do osteocytes respond appropriately to relevant mechanical 
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stimuli?  This complex question must consider the contributions of membrane proteins, 
lipids, intracellular signals, and the cytoskeleton, all of which convert mechanical forces 
into biochemical signals that ultimately alter gene expression. No aspect of 
mechanotransduction in bone may be more fundamental than, yet as controversial as, 
identification of the predominant cell surface mechanoreceptor. It is probable that no 
single mechanoreceptor protein or structure is singularly responsible for sensing and 
transducing mechanical stimuli into altered bone formation. Fortunately excellent 
progress is being made and great potential exists to therapeutically manipulate 
mechanotransduction pathways to treat human bone mass diseases.  
Bone cell mechanoreceptors can be classified into broad categories; i) integrins, 
ii) G-protein coupled receptors/receptor tyrosine kinases, and iii) ion channels/connexin 
hemichannels). A role for the primary cilium is also gaining acceptance. Inhibition of a 
specific protein’s ability to blunt normal mechanotransduction is the standard of proof 
that a protein is involved in vitro. However, most in vitro studies fail to recapitulate the 
complex 3-dimensional environment of osteoblasts and osteocytes in vivo, and it is more 
challenging to determine which proteins are essential in vivo.  While it is likely that any 
predominant mechanoreceptor would be activated within milliseconds of stimulation, 
temporal and quantitative assessment of mechanical signaling activity in real time in 
living cells within bone is extremely difficult.  
Integrins/Focal Adhesions 
Integrins as mechanosensors at specialized sites of cell-matrix adhesion, known as “focal 
adhesions”, have been intensively studied [17]. Integrin-containing focal adhesions 
mediate both cell-matrix adhesion and transmembrane signaling. Responses to strain and 
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fluid flow mediated by integrins in bone cells, initially studied in osteoblast-like cells, 
and more recently in osteocytes, include changes intracellular tension via reorganization 
of the actin cytoskeleton, increased MAP kinase and tyrosine kinase activity, release of 
paracrine signaling molecules (prostaglandins and nitric oxide), and altered gene 
expression. These findings led to the “mechanosome hypothesis” (Figure 3) which 
postulated that protein complexes (mechanosomes) capable of associating with cell 
adhesion molecules (integrins and cadherins) are “launched” from the membrane to the 
nucleus in response to mechanical stimuli, leading to alteration of gene expression [18]. 
DNA-binding proteins localized in adhesion molecule-associated complexes are 
translocated to the nucleus in response to mechanical loading, thereby transferring 
mechanical information from adhesion complexes at the cell surface to target genes [19]. 
Experimental support is based largely on the effects of deleting/inhibiting specific 
mechanosome proteins on signaling and load-induced bone formation.  
Evidence that integrins are activated by fluid flow is compelling and comes both 
from direct demonstration of changes in integrin conformation and from studies using 
integrin-specific inhibitory antibodies and function inhibiting Arg-Gly-Asp (RGD) 
peptides.  Thus, focal adhesions exhibit many properties implicating them as primary 
mechanosensory structures [20].  Importantly, integrins have two interrelated roles: a 
structural (load-bearing) function in which they link (indirectly) to the actin cytoskeleton, 
and a signal transduction/scaffolding function in which they bind and organize proteins 
that have significant downstream effects on the cell. Although cytoskeletal reorganization 
received considerable initial attention as a mechanism for transducing mechanical 
signals, many biochemical responses to mechanical stimulation in bone cells do not 
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require an intact 
cytoskeleton [21]. 
Conformational 
changes induced by 
mechanical stimuli 
expose binding sites 
in the cytoplasmic 
tails of integrin 
subunits. These are 
binding sites for 
kinases (focal 
adhesion kinase 
[FAK], proline rich kinase-2 [Pyk2], Src kinase) and adaptor proteins (e.g., paxillin, β-
actinin, Nmp4, zyxin, p130cas, among many others) that can stimulate signaling cascades 
and translocate mechanosome complexes from the cell membrane into the nucleus in a 
multi-stop process involving detection of a mechanical signal, activation of membrane-
associated proteins, formation of mechanosome complexes at the membrane, and then 
their translocation to the nucleus where they alter transcription of genes that regulate 
bone remodeling.  
G-protein and receptor tyrosine kinase signaling in mechanotransduction 
Osteocyte responses to mechanical load include activation of G-protein coupled receptors 
(GPCRs).  GPCRs are a large class of surface receptors stimulated by a wide range of 
ligands. The most common method of monitoring GPCR activity is though measuring 
Figure 3. Mechanotransduction signaling in osteocytes. In response to 
mechanical stimulation (fluid flow or ECM deformation), numerous 
signaling pathways are activated. Figure from [2]. 
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hydrolysis of the G-proteins that they activate. The Frangos lab showed that fluid shear 
stimulates G-protein signaling and that pharmacologic inhibition of G-proteins inhibits 
activation of downstream signals [22]. The temporal and spatial advantages of 
fluorescence resonance energy transfer (FRET) microscopy allowed them to demonstrate 
that a conformational change occurs in the parathyroid hormone 1 receptor (PTH1R) and 
B2 bradykinin receptor within milliseconds of applying fluid shear stress [23]. This 
response did not require the presence of either receptor’s ligand and could be modulated 
by changing membrane fluidity, showing that these receptors exhibit the characteristics 
required of direct cell surface sensors of mechanical stimuli.  
Molecular interplay between receptor tyrosine kinase (RTK) signaling and 
integrins was shown by the Bikle laboratory who reported that signaling through the 
insulin-like growth factor 1 receptor (IGF1R) is required for optimal transduction of fluid 
shear induced signaling and is also regulated by direct interaction with integrins [24]. 
This led to their proposing a model in which the bone forming effects of IGF1 are not 
only mediated by interactions with IGF1R but can simultaneously be modulated by 
mechanical stimulation of integrins and pathways downstream of integrins. The Pilz lab 
showed that fluid shear mediated activation of nitric oxide, cyclic GMP and protein 
kinase G signaling in osteoblasts was dependent on Src activation downstream of 
integrins [25]. This process involved PKG II dependent Src dephosphorylation via a fluid 
shear induced PKG II/Src/Shp mechanosome. Whether GPCRs and RTKs are able to 
sense mechanical stimuli directly, or do so primarily via cross-communication with 
integrin mechanosensor remains to be determined.  
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Gap Junctions/Ion Channels in mechanotransduction 
Gap junction channels formed by connexins (Cx) mediate communication among 
osteocytes and between osteocytes and cells on the bone surface [26]. All bone cells 
express connexins, Cx43 being the most abundant. In vitro and in vivo studies showed 
that Cx43 protein levels and function are increased by mechanical stimulation and 
conversely, lack of mechanical signals decreases Cx43 expression. 
Cx43 also forms hemichannels that enable communication between cells and the 
extracellular environment [27] and are opened by mechanical stimulation [26], although 
their function is still under debate. It has been proposed that hemichannels are required 
for ATP and prostaglandin release induced by mechanical stimulation. However, another 
study showed that activation of purinergic receptors increases prostaglandin E2 (PGE2) 
release independent of hemichannels, and that blockade of P2X7 receptors, which are 
activated by ATP, prevents PGE2 release from osteoblastic and osteocytic cell lines. 
Further, it was recently shown that that osteoblastic cells derived from Cx43-/- mice still 
respond to mechanical stimulation by releasing PGE2 [26]. This later study proposes that 
hemichannels formed by Pannexin1, a transmembrane protein with topology similar to 
connexins [28], rather than Cx43 are responsible for channel activity induced by ATP in 
osteoblastic cells. 
In vitro studies, together with early evidence showing the existence of gap 
junctions between osteocytes and osteoblasts on the bone surface [29], led to the 
hypothesis that Cx43 is required for the response to mechanical stimulation in vivo. This 
was proven in mice lacking Cx43 in pre-osteoblasts, osteoblasts and osteocytes, which 
exhibit an attenuated anabolic response to mechanical stimulation on the tibial 
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endocortical surface [26]. However, all studies in which periosteal bone formation was 
investigated showed, surprisingly, an enhanced response to mechanical loading in the 
absence of Cx43 in osteochondroprogenitors, osteoblasts, and osteocytes. The molecular 
bases for this effect remains unknown. 
Mechanotransduction can be modulated by extracellular nucleotides [30]. ATP 
and UTP are released by osteoblasts and osteocytes subjected to mechanical stimulation 
in vitro, and can activate P2X ligand-gated ion channels and metabotropic P2Y GPCRs 
[31]. Receptor activation leads to various responses depending on the nucleotide and type 
of receptor, including Ca2+ wave propagation, intracellular kinase activation, modulation 
of osteoblast function and survival. In particular, P2X7-deficient mice exhibit a deficient 
anabolic response to mechanical stimulation in vivo, suggesting an important role for 
these channels in mechanotransduction [32]. Further, a complex formed by P2X7 
Figure 4. Gap junctions and hemichannels in osteocytes. Gap junctions are necessary of 
mechanotransduction in osteocytes. Cx43 in osteocytes is involved in the response to mechanical 
stimulation in bone. Figure from [2]. 
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receptors and pannexin1 channels mediates ATP release induced by mechanical 
stimulation in vitro [33]. The relevance for this complex in transmission of mechanical 
signals in vivo remains to be determined (Figure 4).  
Ion channels sensitive to mechanical stimulation are also found in osteoblastic 
cells [34, 35]. Among them, gadolinium-sensitive stretch-activated cation channels are 
involved in the response to stretching in vitro. In addition, transient receptor potential 
channels and voltage gated calcium channels (VGCC) mediate the propagation of 
calcium waves following mechanical stimulation in osteoblastic cells. Interestingly, 
osteoblast to osteocyte differentiation is accompanied by changes in the type of VGCC 
from L-type in osteoblasts to T-type in osteocytes, a change associated with the different 
sensitivity of the two cell types to mechanical stimulation [36]. The role of VGCC 
channels in mechanotransduction has been demonstrated in vivo, as inhibition of L-type 
channels in rats blocks the anabolic response to loading [34].  
Biochemical responses to mechanical stimuli 
Detection of a molecular response to mechanical stimulation does not prove that it is 
important for mechanotransduction in bone. Determining which are important to 
regulating bone responses to mechanical stimulation and which are merely tangential is a 
critical question if we are to effectively target mechanotransduction pathways for 
therapeutic benefit. The following signaling pathways have been verified in vivo to affect 
the skeleton. 
Prostaglandin and NO signaling 
Osteoblasts and osteocytes secrete prostaglandin E2 (PGE2) and upregulate expression of 
cyclooxygenase 2 (COX2) in response to substrate strain and fluid flow [37]. COX2 is 
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necessary for PGE2 production, and inhibition of COX2 using inhibitors such as NS398 
blocked PGE2 release in vitro.  PGE2, a lipid generated from arachidonic acid via COX 
enzymes that functions like a hormone, is secreted in response to a number of stimuli 
including PTH, estrogen and mechanical loading.  Vigorous exercise in humans results in 
rapid release of PGE2 from loaded lower limb bones [38].  In mice, mechanical loading 
upregulated COX2 mRNA and protein within minutes [39]. A functional role for PGE2 
signaling on the skeleton in response to mechanical loading was shown in vivo by 
pharmacologic inhibition of both COX1 and COX2 using indomethacin, or via selective 
inhibition of COX2 alone using NS398 [40]. In both cases, inhibition of PGE2 
production prior to loading reduced the osteogenic response. PGE2 secretion studies from 
bone cells in vitro suggest PGE2 is released through connexin-43 hemichannels or from 
purinergic P2X7 protein complexes [41].  Downstream of PGE2 release, autocrine and/or 
paracrine effects may be mediated via Ep receptors. 
Nitric oxide (NO), a free radical that diffuses like a gas very rapidly through the 
plasma membrane, is released from osteoblasts and osteocytes in response to fluid shear 
and strain. Depletion of NO in vivo prior to loading in rats using NOS inhibitors 
attenuates the osteogenic response to loading.  Unlike WT animals, mice null for 
inducible NOS (iNOS-/-), failed to reform bone that is lost during hindlimb unloading 
upon returning to normal ambulation, suggesting that the cellular response to mechanical 
stimulation in bone requires NO signaling [42].  
One of the key pathways that osteocytes use to facilitate mechanotransduction is 
the Wnt signaling pathway, which is gaining recognition as a key player in adaptive bone 
modeling and remodeling.   
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Wnt signaling impacts bone mass and strength  
The role of Wnt signaling in bone mechanotransduction is of critical importance, and it 
serves as the basis for most of the work associated with this dissertation.  Our 
understanding of osteocyte mechanotransduction took a significant leap forward when the 
importance of Wnt signaling in bone was identified (Figure 5).  Prior to the turn of this 
century, research on the Wnt signaling cascade was confined largely to the cancer (e.g., 
tumor biology and proliferation) and developmental biology (e.g., axis patterning) fields.  
However, two key clinical discoveries changed our view on where and how Wnt 
signaling is important in the body, bringing the skeleton into direct focus as a major Wnt-
dependent system.  The first of these discoveries was the finding that loss-of-function 
mutations in the Wnt co-receptor Low density lipoprotein receptor-related protein 5 
(LRP5) are a genetic cause of the rare, debilitating disease Osteoporosis Pseudoglioma 
(OPPG) [43].  Patients with OPPG can present clinically with bone mineral density 
(BMD) values that are approximately 5 standard deviations below age-matched normal 
values, resulting in frequent fractures and impaired mobility.  At around the same time, 
other groups reported that gain-of-function mutations in LRP5 are a genetic cause for 
endosteal hyperosteosis, a high bone mass (HBM) condition [44, 45].  These patients 
have BMDs that are approximately 5 standard deviations above normal, but their 
skeletons are relatively normal in shape, and they present with none of the clinical 
manifestations associated with other, osteoclast-mediated sclerosing bone disorders (e.g., 
osteopetrosis).  Thus, within a few short years, a single Wnt co-receptor was identified as 
causative for two very different rare skeletal diseases, one associated with very high bone 
mass and the other associated with very low bone mass.  As LRP5 has no other well-
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characterized primary ligands beyond the Wnt family, these human genetic studies 
implicated Wnt signaling as a major regulator of bone metabolism.   
Wnt signaling participates in mechanotransduction  
Shortly after the discoveries regarding LRP5’s role in regulating human skeletal 
properties, mouse models were developed to model the diseases in mice and open up 
experimental options not possible in human patients.  Mice with loss-of-function 
mutations in Lrp5 (i.e., “knockout”) recapitulate the low bone mass phenotype observed 
in human OPPG patients (Figure 6A).  These mice have low BMD, compromised 
Figure 5. Wnt signaling pathways in bone. Wnt signaling is inhibited by soluble factors 
including Sost, Dkk1 and Sfrp, among others. During inhibition of Wnt, the GSK-3β/APC/Axin 
complex phosphorylates β-catenin, leading to proteasome-mediated degradation of β-catenin. 
When Wnt signaling is activated, Lrp5/Axin/Fzd complex inhibits GSK-3β and β-catenin 
accumulates in the cytoplasm. From there, β-catenin is utilized for gap junction formation, 
integrin complexes and as a transcription factor in the nucleus (shown). Figure from [5]. 
18 
trabecular mass and 
architecture, reduced 
cortical bone size, and 
impaired biomechanical 
properties [46].  Those 
observations prompted 
investigation into the role 
of Wnt signaling in 
mechanotransduction, the 
first experiments of 
which began by looking at 
mechanoresponsiveness in 
Lrp5-/- mice.  In vivo mechanical loading experiments, using the rodent ulnar loading 
model, were first performed to assess the ability of Lrp5-/- mice to respond anabolically to 
a simulated vigorous exercise session.  In both male and female Lrp5-/- mice, load-
induced bone formation was significantly impaired compared to control (wild-type; WT) 
mice [46] (Figure 6B).  That conclusion was later confirmed by another group in an 
independently generated Lrp5 knockout model, using a different loading modality (tibia 
loading) [47].  Thus the experimental data are consistent in implicating Wnt signaling 
through Lrp5 as a crucial process for skeletal mechanotransduction. i.e., without Lrp5 
receptors, bone tissue cannot adapt properly to mechanical inputs.  Those observations 
might explain a portion of the low bone mass phenotype among OPPG patients, i.e., that 
Figure 6. Lrp5 is critical for the response to mechanical load in 
bone. Lrp5 KO mice have reduced bone mineral content (A) and 
reduced bone formation in response to loading (B). Lrp5 HBM 
mice are more sensitive to mechanical stimulus (C). Figure from 
[3]. 
19 
these individuals are unable to respond to otherwise stimulatory mechanical signals, and 
consequently, bone properties never reach their appropriate size and strength.  
While the Lrp5 knockout models are useful for exploring the role of the Wnt/Lrp5 
axis in bone metabolism and mechanotransduction, the field saw a developing interest in 
understanding whether the gain-of-function mutations in LRP5 found in several families 
with HBM might also confer improved mechanical signaling properties to the cell.  
Different knock-in mouse lines, harboring a variety of HBM-causing missense mutations 
in Lrp5 were developed to study the HBM phenotype.  Like the human patients that these 
mutations were modeled after, the HBM knock-in mice exhibited high BMD, 
dramatically increased trabecular 
and cortical bone mass, and 
improved biomechanical 
properties [48].  More importantly, 
however, the gain-of-function 
mutant mice were more responsive 
to tibial loading than their WT 
littermates (Figure 6C) [49].  In 
summary, mice with either loss- or gain-of-function mutations in Lrp5 exhibit altered 
load-induced bone formation, suggesting that Lrp5 plays a major role in 
mechanotransduction signaling in bone. 
Osteocytes are the cell type of action for Wnt-mediated modulation of bone mass   
While both the gain-of-function knock-ins, and the loss-of-function knockout, all model 
the phenotypes observed human patients with analogous LRP5 mutations (i.e., the mice 
Figure 7. Lrp5 mutations in bone alter bone mass. (A) 
Deletion of Lrp5 in osteocytes reduces bone mass, 
whereas mutation in Lrp5 resulting in increased Lrp5 
function (B) increases bone mass. Figure from [3]. 
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and humans have altered Lrp5 expression globally), those mouse models do not reveal 
the specific cell type(s) of action that account for the Wnt-driven skeletal phenotypes.  To 
address this issue, cell-selective deletion of Lrp5 or expression of Lrp5-HBM alleles in 
specific cell types can reveal the relative contributions of these cell types to the overall 
phenotype.  Mice with floxed Lrp5 alleles (Lrp5f/f), where recombination of the LoxP 
sites results in a null allele, have a normal bone mass in the absence of Cre recombinase.  
However, when crossed to mice that express Cre in osteocytes (Dmp1-Cre), the mice 
develop an early-onset osteopenic phenotype that mimics the global Lrp5-/- model (Figure 
7A) [48].  Likewise, mice engineered with a Cre-inducible heterozygous gain-of-function 
missense mutation in Lrp5, where recombination of a floxed Neo cassette in one of the 
introns releases the HBM allele from its dormant state, have normal bone mass in the 
absence of Cre recombinase.  However, when crossed to mice that express Cre in 
osteocytes (Dmp1-Cre), the mice develop an early-onset hyperostosis phenotype that 
mimics the global Lrp5-HBM model (Figure 7B) [48].   Thus, the osteocyte-selective 
deletion of Lrp5 and expression of Lrp5-HBM both recapitulate the global knockout and 
knock-in models, respectively, suggesting that mutation of Lrp5 in the osteocyte 
population (or at least in the 10kbDmp1-expressing population) is sufficient to recapitulate 
the bone phenotype of body-wide mutation.  These data implicate the osteocyte as the 
cell type of action for Wnt/Lrp5-mediated signaling in the modulation of bone mass.   
Osteocytes are the cell type of action for Wnt-mediated mechanotransduction 
Given the discovery that Lrp5 signaling in the osteocyte population accounts for the 
skeletal effects of this receptor, additional work was performed to determine whether 
Wnt/Lrp5-mediated mechanotransduction was localized to the osteocyte.  As described 
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above, crossing Dmp1-Cre mice to Lrp5f/f mice deletes Lrp5 selectively in the osteocyte 
population.  When subjected to ulnar loading, these mice have a severe deficit in load-
induced bone gain [50], much like the global Lrp5-/- mice (Figure 8) [46].  Because the 
osteocyte is a key cell type for Wnt/Lrp5-mediated mechanotransduction, the obvious 
next step was to look for cellular mechanisms that might control Lrp5 signaling 
specifically in osteocytes, potentially explaining the normal mode of action for the Lrp5 
receptor in a typical mechanical signaling event.  This work was focused on Wnt/Lrp5 
modulators that were enriched in osteocytes, and the most obvious molecule is sclerostin.  
In the skeleton, sclerostin expression is localized largely to the osteocyte population, to 
the exclusion of other skeletal cells [51].  Moreover, loss of sclerostin either by mutations 
in the SOST coding sequence [52], or by deletion of downstream SOST enhancer regions 
[53], results in very high bone mass.  Those two attributes, in addition to the observation 
that sclerostin is a high-affinity Lrp5 antagonist [54], has fueled inquiries into whether 
sclerostin is a key mediator of Lrp5-mediated mechanotransduction.  Sclerostin transcript 
and protein levels are dramatically reduced by mechanical loading, and the degree of 
down-regulation is closely associated with strain magnitude [55].  Thus, a load-induced 
reduction in local sclerostin levels appears to be a reasonable explanation as to how Lrp5 
achieves activation during loading.  In that context, mechanical stimulation induces a 
down-regulation of sclerostin protein, which releases Lrp5 from inhibition, and promotes 
Wnt local Wnt signaling through Lrp5.  If this model is true, it would require that 
sclerostin must undergo downregulation in order for mechanotransduction to occur.  
Testing this hypothesis directly with a functional study is challenging but not impossible, 
in that it would require applying mechanical loading to a mouse model in which 
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sclerostin levels could be maintained at a high level, even in the presence of a mechanical 
stimulus (which normally causes Sost downregulation).  Those experimental conditions 
were achieved by using the Dmp1-hSOST transgenic mouse model.  This mouse harbors 
a transgene comprising a human SOST cDNA under the control of the mouse Dmp1 
promoter [56].  The Dmp1 promoter is load-responsive in the positive direction, i.e., 
Dmp1 expression is increased in response to a mechanical stimulus [57].  In the Dmp1-
hSOST transgenic mouse, mechanical loading induces the predicted downregulation of 
endogenous Sost expression (as would occur in a WT mouse), but at the same time 
induces an upregulation of transgenic hSOST expression, due to a load-induced increase 
in Dmp1 promoter activity.  Therefore this mouse can maintain high levels of sclerostin 
protein even in the context of mechanical loading.  When subjected to ulnar loading, the 
Dmp1-hSOST exhibits a nearly complete lack of mechanoresponsiveness (Figure 8), 
which phenocopies the Lrp5-null mechanoresponsiveness [56].  In summary, numerous 
functional studies suggest that osteocyte Wnt/Lrp5 signaling is crucial for skeletal    
mechanotransduction, and the process appears to be regulated by the secreted Lrp5 
antagonist sclerostin.  
Wnt-mediated mechanotransduction during mechanodeprivation 
Although portions of the extracellular membrane components of Wnt signaling, such as 
Sost and Lrp5, have been explored in the mechanotransuctive response, the intracellular 
Figure 8. Sost 
prevents loading 
response in bone. 
Mice expressing the 
Dmp1-hSost 
transgene do not 
respond to 
mechanical load. 
Figure from [3]. 
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downstream signaling molecules, such as β-catenin, have a more poorly defined role in 
bone. β-catenin is a downstream mediator of canonical Wnt, and activation of Lrp5 leads 
to stabilization of β-catenin and changes in gene expression. As mentioned above, Lrp5 
and Sost are involved in the load-induced anabolic bone response. These genes are also 
involved in modulating reductions in bone mass that accompany disuse. For example, the 
expression of High Bone Mass (HBM)-causing missense mutations in Lrp5 or genetic 
deletion of Sost leads to an osteoprotective phenotype when mechanical stimulation is 
removed by disuse models (tail suspension or botox injection). However, it is unclear 
what downstream molecular mechanisms are altered in this response, or if increased 
levels of β-catenin would generate the same osteoprotective phenotype. Recent studies 
have evaluated the role of β-catenin in osteocytes but have not evaluated its role in disuse 
mechanotransduction. We and others have reported that deletion of β-catenin in 
osteocytes results in decreased response to enhanced loading [58, 59], and the Bonewald 
lab has reported that haploinsuffiency of β-catenin prevents bone loss during disuse [60], 
but the potential osteoprotective effects of β-catenin stabilization on disuse-induced bone 
wasting are not known.  
More recently, sclerostin-mediated antagonism of Lrp5 appears to require a 
“facilitator” protein, without which the full inhibitory effects of sclerostin are not 
achieved.  The facilitator protein has been identified as Lrp4 [1], another LDL-like family 
member that has important functions in neuromuscular junction architecture [61].  Lrp4 
antagonizes Wnt activation by binding inhibitors such as Sost, Wise (Sostdc1), and 
potentially Dkk1.  A new form of sclerosteosis (SOST2), a human high bone mass 
disease, has been identified in which mutations in Lrp4 lead to bone overgrowth in 
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patients [1]. This same group identified Lrp4 as a 
novel Sost binding partner by tandem affinity 
purification. To date, mouse models of Lrp4 have 
been limited because global deletion of Lrp4 is 
neonate-lethal due to lack of neuromuscular 
junction formation [62, 63]. However, when 
deletion was limited to osteoblasts and osteocytes 
using conditional knockout mice [62], or when 
Lrp4 antibody was administered to wild-type rats 
[63], bone mass was increased, similar to the 
phenotype observed in sclerosteosis patients. A 
mouse model mimicking the human R1170Q 
mutation was recently reported [64], and displayed increased bone mass, although the 
cellular mechanisms underlying the phenotype were not addressed (Figure 9).  Despite 
these recent findings, the role of Lrp4 signaling in bone mechanotransduction has not 
been addressed, and this novel receptor remains poorly characterized, particularly with 
regard to its in vivo biology. Because Lrp4 acts as a putative sclerostin facilitator, it may 
play a critical role in mechanotransduction signaling in bone; if so, it might represent a 
possible therapeutic target for improving bone properties. While genetic deletion of Sost 
leads to an osteoprotective phenotype, in is unclear if loss of Lrp4 function in bone 
prevents the bone-wasting effects seen during disuse.  
In summary, portions of the Wnt signaling cascade have been implicated in the 
mechanotransductive response in bone. However, many questions remain about the 
Figure 9. Mutations in the 3rd 
beta-propeller central domain 
increase bone mass in patients 
with sclerosteosis. Three 
mutations in the central domain 
of Lrp4 3rd beta-propeller results 
in high bone mass in patients. 
This is believed to be a binding 
pocket for Wnt inhibitor Sost. 
Figure adapted from [1]. 
25 
involvement of other components of Wnt signaling (Lrp4), and downstream Wnt 
modulators (β-catenin). Understanding the function of these various components will lead 
to the discovery of potential anabolic bone therapies that may work prevent bone-wasting 
in disease or disuse states, particularly in combination with non-pharmacologic therapies 
such as exercise.  Here, I aim to further understand the role of Wnt pathway components 
in the mechanotransductive response in bone cells. First, I used a constitutively-active β-
catenin mouse model to determine if artificial elevation of β-catenin in the osteocyte 
population protects bone tissue from disuse-induced bone wasting. Next, I evaluated the 
role of Lrp4 in bone homeostasis and mechanotransduction by generating a new mouse 
model that is orthologous to the HBM patients carrying the R1170W point mutation, and 
conducted experiments to determine the mechanism of action of Lrp4, as well as 
characterize Lrp4 as a possible therapeutic bone target.  
Here, I hypothesize that two components of the Wnt signaling pathway, β-catenin 
and Lrp4, are critical for the osteocyte mechanotransduction response. Specifically, in the 
absence of normally functioning β-catenin or Lrp4, mechanodepravation-induced bone 
loss will be reduced. 
Aim 1: Determine the susceptibility to disuse‐induced bone loss following constitutive 
activation of β‐catenin in osteocytes. Extracellular and membrane‐bound components of 
canonical Wnt signaling appear to affect disuse‐ induced bone loss. I will generate mice 
with mutations in the intracellular Wnt mediator β‐catenin, to understand whether this 
canonical node can be targeted to prevent bone wasting from disuse. I will generate mice 
with tamoxifen‐inducible gain‐of‐function (floxed exon 3) mutations in β‐catenin in late-
stage osteoblasts/osteocytes using the 10KbDmp1‐CreERt2 driver, and assess the degree 
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of bone loss resulting from tail suspension and Botox injection. I will monitor bone loss 
radiographically and histologically, and look for changes in transcriptome‐wide RNA 
expression using RNAseq from bone‐derived transcripts [65] that might highlight novel 
targets for preventing bone loss from disuse. 
Aim 2: Determine the role of Lrp4 3rd beta-propeller central domain in sclerostin action 
in bone homeostasis and mechanodeprevation. Mutations in patients within the central 
domain of the Lrp4 3rd β-propeller result in high bone mass disease. I will generate a 
mouse model with the R1170W mutation in Lrp4 to mimic patients and recapitulate this 
phenotype in a model for experimental manipulation. I will then expose this model to 
altered levels of circulating sclerostin by genetic manipulation or pharmacological 
methods. Finally, I will determine the necessity of sclerostin binding to Lrp4 in disuse. 
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Chapter 2: Materials and Methods 
Generation of mouse models 
β-catenin Constitutively Active mouse models  
All mice used in the experiments harbored one floxed gain-of function β-catenin allele 
(exon 3 flox, hereafter referred to as constitutively active, or “CA”) and one floxed loss-
of-function β-catenin allele (exon 1-6 flox, hereafter referred to as loss-of-function, or 
“LOF”).  Both gain-of function and loss-of-function β-catenin alleles have been described 
previously [66, 67].  Briefly, βcatCA mice contain LoxP sites flanking exon 3, which 
houses the code for the Gsk-3β phosphorylation site (required for degradation) of the β-
catenin protein.  βcatLOF mice harbor LoxP sites in introns 1 and 6 of the βcat (Ctnnb1) 
gene, which results in a null allele upon recombination of the LoxP sites.  In the 
combined βcatCA/LOF mouse model that I bred, both alleles behave as wild-type prior to 
recombination.  After Cre-mediated recombination, the mice are essentially heterozygous 
for the CA allele, as the LOF allele becomes null.  I chose this approach to produce only 
the degradation-resistant protein in osteocytes, but to do so in a haplo-insufficient context 
to avoid very high levels of active β-catenin within the cell.  10kbDmp1-CreERt2 
transgenic mice have been described previously [68]. These mice harbor a cDNA for the 
Cre recombinase–mutant estrogen receptor fusion protein that results in Cre sequestration 
in the cytosol (away from the chromatin) until the selective ligand tamoxifen is 
encountered [69]. The CreERt2 gene was driven by a 10 kb fragment of the Dentin 
Matrix Protein-1 (Dmp1) promoter, which provides osteocyte and late osteoblast 
selectivity of expression [70]. βcat+/LOF mice were bred to 10 kbDmp1-CreERt2 x 
βcat+/CA mice to generate littermate βcatCA/LOF mice that were either transgenic 
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(hemizygous for CreERt2) or nontransgenic (CreERt2-negative).  Male mice were 
selected for the muscle paralysis experiments, and female mice were selected for tail 
suspension experiments.  Experimental mice were same-sex housed in cages of three to 
five (independent of Cre genotype) and given standard mouse chow and water ad libitum. 
All animal procedures were performed in accordance with relevant federal guidelines and 
conformed to the Guide for the Care and Use of Laboratory Animals (8th Edition). The 
Indiana University animal facility is an AAALAC-accredited facility. 
Cre induction 
To induce adult-onset recombination of the floxed βcat alleles, 12-week old mice were 
treated with 20 mg/kg tamoxifen free base (M&P Biomedicals, Santa Ana, CA). 
Tamoxifen powder was dissolved in dimethyl formamide (DMF) at a concentration of 
100 mg/mL and then suspended in ~150 μL of corn oil for IP injection. Mice that 
received vehicle treatment (no Cre induction) were injected with an equivalent volume of 
DMF alone suspended in 150 μL of corn oil. Mice were treated with single injections of 
tamoxifen or vehicle 3 days prior to the first day of disuse. Details for the experimental 
schedule are shown in Figure 10. 
Lrp4 R1170W knock-in mice 
To generate a new knock-in model of a human patient with an Lrp4 mutation who 
presented with a sclerosteosis-like phenotype [1], the orthologous mutation was 
generated in mice using a Crispr/cas9 approach.  Briefly, a 135bp donor oligo was 
knocked into the 3’ half of Lrp4 exon 25 and adjacent intron.  The donor oligo contained 
a c.3508C→T mutation (plus several local nonsense mutations to facilitate genotyping) 
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that results in an Arg1170Trp substitution (referred to as Lrp4KI).  The Lrp4-R1170W 
knock-in mice were on a fixed C57Bl/6J background. 
Dmp1-hSost mice 
The 8kbDmp1‐hSOST transgenic mouse has been described previously [56]. Briefly, a 
12‐kb DNA fragment containing 8 kb of the 5′‐flanking region, the first exon, the first 
intron, and 17 bp of exon 2 of the murine Dmp1 gene was used to drive expression of a 
human SOST cDNA. The Dmp1‐hSOST mice were on a fixed C57Bl/6J background.     
Dual-energy x-ray absorptiometry (DEXA) 
For β-catenin constitutive activation studies, whole-body DEXA scans were collected on 
isofluorane-anesthatized mice using a PIXImus II (GE Lunar) densitometer. All mice 
were scanned 3 days prior to disuse, and again after 4 weeks of disuse, immediately 
before euthanasia. From the whole-body scans, areal bone mineral density (BMD) and 
bone mineral content (BMC) were calculated for the right and left hindlimbs using the 
Lunar ROI tools.  
For Lrp4KI studies, whole-body DEXA scans were collected on isolfuorane-
anesthetized mice using a Faxitron UltraFocusDXA x-ray densitometer (Faxitron 
Bioptics, Inc., Tucson, AZ). All mice were scanned between the ages of 4 to 18 weeks 
(longitudinal studies) or 3 days prior to the start of the experimental period and again 
immediately before euthanasia (disuse and antibody studies). From the whole-body scans, 
areal bone mineral density (BMD) and bone mineral content (BMC) were calculated for 
the whole body (head and tail excluded) or limbs, depending on the study, using the 
Faxitron ROI tools.   
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Micro-computed tomography (μCT) 
After sacrifice, the proximal half of formalin-fixed tibiae were scanned, reconstructed, 
and analyzed on a Scanco µCT-35 desktop microcomputed tomographer (Scanco 
Medical AG, Brüttisellen Switzerland) as previously described [71].  Briefly, samples 
were scanned at 10-μm resolution (femur, tibia and vertebra) or 20-μm resolution (skull), 
50-kV peak tube potential and 151-ms integration time. Standard output parameters 
related to cancellous and cortical bone mass, geometry, and architecture were measured 
[72]. 
Hindlimb suspension 
For β-catenin constitutive activation studies, eighty 12-week-old female mice were used 
for the hindlimb suspension experiments, comprising 40 mice of each genotype (i.e., 40 
Cre+; βcatCA/LOF and 40 Cre-; βcatCA/LOF).  Each genotype was further divided into 
control and hindlimb-suspended mice with half of each of those subgroups receiving 
tamoxifen and half receiving vehicle (n = 10/group). All mice were individually housed 
following Cre induction/vehicle injection and a tail harness was used to suspend the 
experimental mice as previously described [71]. Control mice were permitted 
unencumbered normal movement in their cages. Mice received intraperitoneal injections 
of alizarin (20 mg/mL) 6 days prior to sacrifice and calcein (10 mg/kg) 3 days prior to 
sacrifice. Mice were suspended for a total of 4 weeks, and euthanasia was performed at 
the end of the 4th week of suspension.   
Botulinum toxin (Botox)-induced muscular paralysis 
For β-catenin constitutive activation studies, eighty 12-week-old male mice were used for 
the Botox experiments, comprising 40 mice of each genotype (i.e., 40 Cre+; βcatCA/LOF 
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and 40 Cre-; βcatCA/LOF).  Each genotype was further divided into control (saline-injected) 
and Botox-treated mice, with half of each of those subgroups receiving tamoxifen and 
half receiving vehicle (n = 10/group).  For Lrp4KI studies, forty 12-week old male mice 
were used for the Botox experiment, comprised of 20 mice of each genotype. Each 
genotype (Lrp4+/+ or Lrp4KI/KI) was further divided into control or Botox-treated mice. 
The right hindlimb musculature (quadriceps, triceps surae, tibialis anterior, hamstrings) 
was injected with 20 μL of Botulinum Toxin A (Botox; Allergan Inc., Irvine, CA), while 
the left hindlimb musculature was left alone and served as an internal control. Control 
mice received 20 μL injections of saline in the right hindlimb in an identical fashion as 
the Botox-treated mice.  The injections (both Botox and saline) were repeated one week 
later to ensure paralysis in the Botox-treated group [71]. Botox efficacy was qualitatively 
evaluated for each mouse every 3-4 days, based on the inability of the treated mice to use 
the limb in normal cage locomotion. 
Protein extraction and Western Blotting 
Protein extraction from mouse bones 
 Immediately after sacrifice, mouse femur, tibia and fibula were dissected, stripped of soft 
tissue, flushed to remove bone marrow. The remaining cortical bone tissue was 
immediately snap frozen in liquid nitrogen and pulverized to a fine powder in a mortar 
and pestle. 800 uL of 4X SDS-PAGE sample buffer was added directly to the mortar 
containing the bone powder, which immediately froze. The extract was thawed, collected, 
heated at 95oC for 5 min, centrifuged at 14,000 x g for 10 min, and the supernatant was 
retained to run directly on gels.  
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Gel electrophoresis and transfer to nitrocellulose 
Approximately 20 µg of protein from each sample was run on a 4-12% polyacrylamide 
gradient gel (GenScript) along with pre-stained molecular weight markers (Bio-Rad).   
Separated proteins were transferred to nitrocellulose overnight, after which the 
membranes were stained with PonceauS to visualize total protein and qualitatively 
evaluate protein loading consistency. Membranes were blocked for 2 hrs in 5% powdered 
milk in TBST (wash buffer) then incubated with primary antibodies (diluted in 5% 
milk/TBST) at 4oC overnight, washed 6X in TBST, then incubated with species-
appropriate HRP-conjugated 2o antibody for 1 hr at R/T. After a final 6X wash in TBST, 
the nitrocellulose was rinsed in deionized water and bound HRP was reacted with ECL 
reagent for 5 min (Amersham, ECL Prime Reagent).  Blots were imaged using an 
iBrightCL1000 (Invitrogen). 
Antibodies 
Mouse anti-β-catenin (Novus Biologicals) diluted 1:2000;  mouse anti-Lrp4 (ab201923, 
Abcam) diluted 1:5000; goat polyclonal anti-sclerostin (AF1589, Sigma) diluted 1:2000; 
mouse monoclonal anti-vinculin (vin11-5, Sigma) diluted 1:5000; HRP donkey anti-goat 
IgG antibody (Jackson) 1:10,000 or goat anti-mouse IgG antibody (Jackson) 1:10,000.  
Quantitative cortical bone histomorphometry 
Mice received injections of demeclocycline (90 mg/kg), alizarin complexone (20 mg/mL) 
and calcein (10 mg/kg) at timepoints outlined in individual experiments. Mice were 
sacrificed 4 weeks after the initiation of disuse.  After µCT scanning, the fixed tibiae and 
femurs were dehydrated in graded ethanols, cleared in xylene, and embedded in 
methylmethacrylate. Thick sections were collected at the tibial and femoral midshafts 
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using a diamond-embedded wafering saw. Sections were ground and polished to ~30 μm, 
mounted and coverslipped, then digitally imaged on a fluorescent microscope. Periosteal 
and endocortical bone formation parameters were calculated at the midshaft by 
measuring the extent of unlabeled perimeter (nL.Pm), single-labeled perimeter (sL.Pm), 
double-labeled perimeter (dL.Pm), and the area between the double labeling (dL.Ar) with 
Image-Pro Plus software (MediaCybernetics Inc., Gaithersburg, MD). The derived 
histomorphometric parameters mineralizing surface (MS/BS), mineral apposition rate 
(MAR), and bone formation rate (BFR/BS) were calculated using standard procedures 
described elsewhere [73]. Relative bone formation parameters were calculated by 
subtracting the disuse (right) limb value from the control (left) limb value for each 
mouse. 
dd-PCR assay for genomic recombination of the conditional β-catenin alleles 
Droplet digital PCR (ddPCR) was performed as previously described [74]. Briefly, 
epiphyseal ends of bone were removed from cleaned long bones, decalcified in EDTA for 
48 hours with gentle rocking and the bone marrow removed by extensive mechanical 
abrasion/washing with a swab and PBS. DNA was extracted from bone pieces using the 
DNeasy Blood and Tissue Kit (Qiagen) and 30 ng of cortical bone DNA was used in 
subsequent PCR reactions. Supermix for Probes mastermix (BioRad, Hercules, CA) was 
used following the manufacturer's recommendations. PCR was performed using 
Eppendorf EP gradient S machines, nanodroplets were created using an automatic droplet 
generator, amplimer containing droplets were counted with a QX200 sample reader, and 
data were analyzed using Quantasoft software (all instrumentation from BioRad). All 
reactions were run in duplicate.  The primer pairs and probes described below were 
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purchased from IDT (Coralville, IA) and were used to amplify and quantify the number 
conditional and recombined alleles. At least 1300 amplimer-containing droplets per 
sample were created in order to measure Cre-mediated recombination. PCR primers.  For 
the LOF allele, three PCR primers (loxP-f: tgaaggcatgcctgcagataacttc, cond-r: 
ctaggctatgtgccccgaca, rec-r: cccttcaatgcttagcaccgt) were used to generate 2 unique 
amplicons – 223bp for the conditional allele and 163bp for the recombined mutant allele. 
Fluorescent probes were designed to complement each amplicon (conditional: 
5HEX/agagcttcctgacaccgtggct /3IABkFQ, recombined: 56-FAM/ cgcgcacacacacacaggctc 
/3IABkFQ). PCR was performed (95°C/10min; 94°C/30sec; 60°C/60sec; 72°C/30sec; 40 
cycles; 98°C/10min; 12°C hold) with cycling ramp time slowed to 1.2sec/°C. For the CA 
allele, thee PCR primers (f: TATCACGAGGCCCTTTCGTC, cond-r: 
cctgaagaagccatctacgaca, rec-r: tcattgcatactgcccgtca) were used to generate 2 unique 
amplicons – 327bp for the conditional allele and 273bp for the recombined mutant allele. 
Fluorescent probes were designed to complement each amplicon (conditional: 5HEX/ 
accctcacctgctctccttggct /3IABkFQ, recombined: 56-FAM/ catgtgggactccgctaccct 
/3IABkFQ) (PCR was performed (95°C/10min; 94°C/30sec; 60°C/60sec; 72°C/30sec; 40 
cycles; 98°C/10min; 12°C hold) with cycling ramp time slowed to 1.2sec/°C. For both 
alleles, template-less water controls were run in every assay to ensure consistency and 
identify any background signal.  
RNA sequencing of osteocyte-enriched cortical bone lysates in tail suspended mice 
Female Cre+ and Cre- βcatCA/LOF (n=4-6/group) mice were used for transcriptional 
analysis.  At 12 weeks of age, Cre-mediated recombination of the βcat alleles was 
induced with tamoxifen as described above. Three days after Cre induction, mice were 
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tail suspended (n=4-6) for 3 days or left alone as ground controls.  On the 4th day, mice 
were euthanized and the tibia and femur cortical tubes (without marrow, periosteum, or 
epiphyses) were prepared for RNA extraction as previously described [75]. Total RNA 
was purified using a Trizol/Qiagen RNeasy Kit prep. RNA quality was assessed using a 
bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). cDNA libraries were 
generated from Poly(A)+-enriched RNA using the Illumina TruSeq RNA Library Prep kit 
v2 (Illumina Inc., Hayward, CA, USA) and the libraries were sequenced using Illumina 
NextSeq 550 sequencer (Illumina Inc., Hayward, CA, USA). RNAseq data (n=3/group) 
quality was checked using FastQC (version 0.11.5) software 
[http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc]. Sequence reads were mapped to 
the mouse reference genome (mm10) using STAR (version 2.6) [76]. After read 
mapping, “featureCounts” from Rsubread package (version 1.30.5)[77] was used to 
perform summarization of reads mapped to RefSeq genes, and gene-wise read counts 
were generated. Genes were filtered from downstream analysis if they did not have CPM 
(counts per million) value of at least 1 in at least three libraries. The data was normalized 
using TMM normalization method [78]. Differentially expressed genes were identified 
using edgeR (version 3.22.3) [79]. A gene was considered significantly differentially 
expressed when its false discovery rate (FDR) corrected p-value was less than 0.05 and 
fold change was greater than 2. Heatmaps were generated using heatmap.2 function in R 
package ‘gplots’.  
Sclerostin inhibition in vivo 
Eight-week-old female mice (Lrp4+/+ or Lrp4KI/KI) were randomized to receive twice-
weekly subcutaneous injections of either sclerostin neutralizing antibody (Scl-mAb) at 25 
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mg/kg (37) or vehicle control for the next 4 weeks (n = 8 mice per genotype and 
treatment group). Scl-mAb doses were adjusted weekly on the basis of body mass 
measurement. Animals were euthanized by CO2 inhalation when 12 weeks old. 
Biomechanical measurements of whole-bone strength 
The left femur was collected from each euthanized mouse, wrapped in saline-soaked 
gauze, and frozen at −20°C until the day of testing. Once femurs had been collected from 
all mice, they were equilibrated at room temperature in a saline bath for 3 hours before 
mechanical testing.  Measures of whole-bone strength were obtained on femurs 
positioned posterior side down across two lower supports (spaced 9 mm apart) of a three-
point bending apparatus. The fixtures were mounted in the frame of a TestResources R 
System test instrument, which has a force resolution of 0.01 N [48]. Each femur was 
loaded to failure in monotonic compression using a crosshead speed of 0.2 mm/s, during 
which force and displacement measurements were collected every 0.01 s. From the force 
versus displacement curves, ultimate force, yield force, stiffness, and energy to failure 
were calculated using standard equations [80]. 
Muscle function testing 
In vivo muscle function in Lrp4 mutant mice was evaluated using the 1305A Whole 
Mouse/Rat Test System (Aurora Scientific Inc., Aurora, ON, Canada) [81] as described 
previously.  Briefly, electrodes were inserted subcutaneously near the tibial nerve in 
anesthetized mice, which were positioned in the instrument to allow ankle dorsiflexion.  
Electrode placement and stimulation current were adjusted to achieve the maximum 
twitch response and then increased to ∼35 mA for plantarflexion to ensure supramaximal 
stimulation of the muscle fibers. The maximum isometric torque (N/m) was recorded for 
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stimulation frequencies between 25 and 300 Hz, with a pulse width of 0.2 ms and strain 
duration of 200 ms. Data were recorded using the Dynamic Muscle Control/Data 
Acquisition and Dynamic Muscle Control Data Analysis programs (Aurora Scientific 
Inc.).  
Statistical analysis 
Statistical analyses were conducted with SigmaPlot. Statistical details of each experiment 
can be found in the figure legends. Statistical significance was taken at p<0.05. Two-
tailed distributions were used for all analyses. Data are presented as means ± SEM.   
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Chapter 3: Constitutive activation of β-catenin in osteocytes protects bones from 
disuse-associated bone wasting. 
Recombination of β-catenin in bone following tamoxifen injection  
I first sought to validate the experimental mouse model by assessing whether the 
tamoxifen-inducible Cre strategy I employed was efficient at recombining the floxed 
constitutively active (CA) -catenin allele.  Specifically, I tested at the protein level 
whether tamoxifen treatment induced the CA allele, and conversely, whether unprovoked 
recombination of the CA allele occurred in the absence of tamoxifen.  To this end, -
catCA/LOF mice that were positive or negative for CreERt2 were raised to 10 weeks of age, 
treated with a single dose of tamoxifen, and sacrificed 3 days later.  Protein was extracted 
from long bone cortices, subjected to SDS-PAGE, transferred to nitrocellulose, and 
blotted for -catenin (Figure 10).  Only mice that were both Cre-positive and exposed to 
tamoxifen produced a significant lower molecular weight band, which is consistent with 
an internally truncated -catenin protein that is 8.5kD lighter when lacking the amino 
acid sequence of exon 3.  Samples were collected just 3 days after a single dose of 
Figure 10. Constitutive activation of β-catenin in bone. A) Timeline of tail suspension and Botox 
experiments. B) Western blot of osteocyte-enriched bone from Dmp1-CreERt2-positive (Cre: +) 
or Dmp1-CreERt2-negative (Cre: -) mice treated with tamoxifen (Tam: +) or corn oil (Tam: -) for 
3 days.  
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tamoxifen, and the larger molecular weight band in these samples may be attributable to 
either residual B-catenin, incomplete recombination or a combination of both factors. 
To assess whether the rates of recombination for the constitutively active (CA) 
and loss-of-function (LOF) alleles were similar, cortical bone genomic DNA was 
extracted from transgenic (TG) and non-transgenic (NTG) catCA/LOF mice treated with 
tamoxifen. ddPCR was performed to generate 1,500 amplimer-containing 
droplets/sample in 3 animals with each genotype.  Primer and probe sets were designed to 
distinguish recombined and non-recombined CA and LOF alleles.  Each ddPCR assay 
was performed in duplicate.  LOF allele recombination rate was 15±3.6% for the βcat 
LOF allele and 11±2.9% for the βcat CA allele in TG tamoxifen treated mice.  The 
different rates of recombination did not differ significantly between the LOF and the CA 
allele (p=0.13) and there was no recombination for either allele in the non-transgenic 
mice.  Thus activation of the CA allele occurred at comparable rates as inactivation of the 
LOF allele in the experimental assays.  However, ddPCR cannot measure the frequency 
with which recombination of each allele occurred in the same cell, nor can it distinguish 
recombination occurred in gDNA recovered from osteocytes or from other cell types 
(e.g., endothelial cells) in the cortical bone extracts.  This latter point is important given 
the recent report of numerous vascular channels in the mouse femoral cortex [82], which 
might easily escape removal during centrifugation and periosteal stripping. 
Tail Suspension Induced Bone Wasting 
To evaluate the bone-wasting effects of a fluid-shift disuse model in mice that have 
impaired ability to degrade -catenin in osteocytes, I measured the effects of tail 
suspension on hindlimb bone mass and density in -catenin stabilized and control mice. 
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During the experimental period, recombination of the -catCA/LOF alleles in ground 
control mice resulted in an 8.7% increase in tibial BMD whereas uninduced (corn-oil 
treated) ground control mice exhibited a 3% increase in tibial BMD mice (Figure 11A).  
Tail suspension was associated with an 8% loss in tibial BMD among uninduced mice, 
whereas activation of the -cat CA allele in tail suspended mice resulted in no change 
(2.5% increase, NS) in tibial BMD, though the activated tail-suspended mice failed to 
gain as much BMD as their activated ground control littermates.  To account for the 
potential confounding effects of tamoxifen on the osteoprotective effects of -catenin 
stabilization during disuse, I conducted additional but identical tail suspension 
experiments using Cre-negative mice. The control experiments revealed that tamoxifen 
alone resulted in an 8.3% increase in tibial BMD (Figure 11C), whereas the corn oil-
treated ground control mice exhibited a 4% increase in tibial BMD. While this tamoxifen-
induced change in ground control mice is similar to that observed among Cre-positive 
mice (a 5.7% increase over oil-treated among the Cre-positive group vs. 4.3% increase 
over oil-treated mice among the Cre-negative group), the osteoprotective effects of 
tamoxifen treatment were completely absent when Cre was not present (and by inference, 
absent -catenin activation) as revealed by an 8.5% decrease in tibial BMD among 
tamoxifen-treated tail-suspended mice not expressing Cre-recombinase in osteocytes 
(versus a 2.5% increase in induced mice following tail suspension). Tibial bone mineral 
content (BMC) followed a similar pattern of bone wasting during disuse, and rescue in 
induced mice (Figure 11B); tail suspension was significantly lower in induced mice, 
although not to the extent of non-activated mice and is likely due to the effect of 
tamoxifen and/or B-catenin activation in activated ground control mice. One exception to 
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the pattern was a stronger effect of -catenin activation in ground control mice, 
independent of tamoxifen. In summary, induction of constitutively active -catenin 
alleles in Dmp1-expressing cells results in protection from tail-suspension induced bone 
loss of whole bone BMD and BMC, which is not attributable to direct skeletal effects of 
tamoxifen treatment.  
Following 4 weeks of tail suspension, tibiae were evaluated for compartment-
specific changes in bone mass, architecture, and dynamic formation indices.  As 
expected, in non-activated mice, proximal tibia cancellous bone volume fraction 
(BV/TV) was reduced significantly by tail suspension (24.2% reduction, p<0.05; Figure 
12A).  Activation of -catenin in ground control mice induced a slight but non-significant 
increase in BV/TV (12.7% increase, NS), which was not significantly affected by tail 
suspension (5.8% increase, NS).  In contrast, the parallel experiment conducted in Cre-
negative mice revealed a significant loss of BV/TV in tamoxifen treated mice (Figure 
12E), which suggests that the bone-sparing effects of -catenin activation seen in the tail-
suspended Cre-positive mice was not a result of tamoxifen. Other µCT parameters (Tb.N, 
Tb.BMC) showed similar effects as noted for BV/TV, with the exception of trabecular 
thickness (Tb.Th), which was not rescued in induced tail-suspended mice.  In summary, 
induction of constitutively active -catenin alleles in Dmp1-expressing cells results in 
protection from tail-suspension induced deterioration of trabecular bone structural 
parameters, most of which is not attributable to direct skeletal effects of tamoxifen 
treatment.   
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Figure 11. Mice with constitutive activation of β-catenin are protected from 
mechanodeprivation-induced bone loss during 4 weeks of tail suspension. Percent change in 
tibial bone mineral (A,C) density and (B,D) content, calculated from DXA scans collected just 
prior to the start of the experiment and again at sacrifice following 4 weeks of tail suspension for 
Cre-positive and Cre-negative mice. N=10/group Data were tested using 2-way ANOVA with 
Tamoxifen/oil and the tail suspension as main effects.  Inset at the top of each graph indicates 
significance of the main effects and interaction (#=Tamoxifen/Oil  p<0.05; @=Tail suspension 
p<0.05; †=interaction p<0.05).  When at least one term was significant, Fisher’s PLSD post-hoc 
tests were conducted between ground control and tail suspended mice and are indicated as 
*p<0.05. 
A B 
C D 
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Dynamic cortical bone formation parameters were measured over the 
experimental period using fluorochrome labels administered throughout the treatment 
period.  Bone formation parameters on both endocortical and periosteal surfaces were 
minimal in uninduced mice subjected to tail suspension (Figure 13A and B).  Activation 
of -catenin had an effect on bone formation at the periosteal (2-fold increase, p<0.05) 
but not endocortical surface in ground control mice, which could be fully explained by 
tamoxifen effects (Figure 13D).  However, as reported for the DXA measurements, 
tamoxifen treatment alone had no protective effects on tail-suspension-induced 
suppression of bone formation parameters.  In summary, induction of constitutively 
active -catenin alleles in Dmp1-expressing cells results in protection from tail-
suspension induced reduction in endocortical and periosteal bone formation rates, which 
is not attributable to direct skeletal effects of tamoxifen treatment. 
Botulinum Toxin (Botox)-Induced Bone Wasting  
After learning that activating β‐catenin alleles in Dmp1-expressing cells conferred 
protection from the bone-wasting effects of tail suspension, I employed a second model 
of bone wasting to evaluate whether degradation-resistant -catenin had broader efficacy 
for disuse in general.  I measured the bone-wasting effects of muscle paralysis-induced 
disuse, using intramuscular injection of botulinum toxin (Botox) in Dmp1-CreERt2  
catCA/LOF mice and used the contralateral uninjected limb as a control. During the 
experimental period, recombination of the -catCA/LOF alleles in saline-injected control 
mice resulted in a 9.1% increase in tibial BMD in the treated limb, whereas uninduced 
saline injected control mice exhibited a 1.8% (NS) increase in tibial BMD (Figure 14A). 
Botox injection was associated with a 10.8% loss in tibial BMD among uninduced (corn 
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oil treated) mice, whereas activation of the -cat CA allele in mice treated with Botox 
resulted in a slight loss (-5.6%, NS) in tibial BMD. To account for the potential 
confounding effects of tamoxifen, I conducted identical Botox experiments in Cre-
negative mice. Tamoxifen alone resulted in a 3.9% increase (NS) in tibial BMD (Figure 
14C), whereas the corn-oil treated saline control mice exhibited a 0.4% reduction (NS) in 
tibial BMD. The tamoxifen-induced change in Cre-negative ground control mice is about 
Figure 12. μCT measurements of cancellous bone properties in the tibiae of ground control 
and tail suspended Cre-positive and Cre-negative cat CA mice. (A,E) Bone volume fraction, 
(B,F) trabecular number, (C,G) trabecular thickness, and (D,H) trabecular bone mineral content 
were measured in the proximal tibia. N=8-10/group Data were tested using 2-way ANOVA with 
Tamoxifen/oil and the tail suspension as main effects.  Inset at the top of each graph indicates 
significance of the main effects and interaction (#=Tamoxifen/Oil  p<0.05; @=Tail suspension 
p<0.05; †=interaction p<0.05).  When at least one term was significant, Fisher’s PLSD post-hoc 
tests were conducted between ground control and tail suspended mice and are indicated as 
*p<0.05. 
A B C D 
E F G H 
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half of the effect seen Cre-positive ground control mice, suggesting that induction of the 
-cat CA allele has positive effects on BMD in ground control mice.  However, as 
reported for the tail suspension studies, the osteoprotective effects of tamoxifen treatment 
alone on Botox-induced bone loss were completely absent (14% decrease in tibial BMD 
in tamoxifen-treated vs. 15.7% decrease in corn oil treated), again, suggesting that the 
Figure 13. Dynamic histomorphometry of Cre-positive and Cre-negative cat CA mice following 
tail suspension. Fluorochrome labels were administered 3 days apart and measured for single label 
length, double label length and double label area on endosteal and periosteal bone surfaces. 
Endosteal bone formation rate (A,C), as well as  periosteal bone formation rate (B,D) were 
calculated. (E) Representative images of the endocortical surface of Cre-positive mice. Mice were 
given fluorochrome labels (red and green) 5 and 3 days prior to the end of the disuse period. 
N=3/6/group. Data were tested using 2-way ANOVA with Tamoxifen/oil and the tail suspension 
as main effects.  Inset at the top of each graph indicates significance of the main effects and 
interaction (#=Tamoxifen/Oil  p<0.05; @=Tail suspension p<0.05; †=interaction p<0.05).  When 
at least one term was significant, Fisher’s PLSD post-hoc tests were conducted between ground 
control and tail suspended mice and are indicated as *p<0.05. 
A B 
C D 
E 
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protection from botox-induced bone loss was attributable to activation of -cat CA. 
Tibial bone mineral content (BMC) followed a similar pattern of bone wasting during 
disuse, and rescue in induced mice (Figure 14B).  In summary, induction of constitutively 
active -catenin alleles in Dmp1-expressing cells results in protection from paralysis-
induced loss of whole bone BMD and BMC, which is not attributable to direct skeletal 
effects of tamoxifen treatment.   
  Following 4 weeks of muscle paralysis induced by treatment with Botox, tibia 
were evaluated for compartment-specific changes in bone mass and architecture indices.  
As expected, in uninduced mice, proximal tibia cancellous bone volume fraction 
(BV/TV) was reduced significantly by Botox injection (43% reduction, p<0.01; Figure 
15A), relative to the contralateral control limb.  Activation of -catenin in saline-injected 
control mice induced a slight but nonsignificant decrease in BV/TV (8% decrease, 
P=0.813), which was not significantly affected by Botox treatment (12.8% decrease, 
P=.480).  In contrast, the parallel experiment conducted in Cre-negative mice revealed a 
significant loss of BV/TV in tamoxifen treated mice that also received Botox injection 
(Figure 15E), which suggests that the bone-sparing effects of -catenin activation seen in 
the Botox-injected Cre-positive mice was not a result of tamoxifen effects.  Tb.BMC 
showed similar effects as noted for BV/TV, with the exception of trabecular thickness 
(Tb.Th), which was not rescued in induced Botox mice, and Tb.N, which was not 
different among groups.  In summary, induction of constitutively active -catenin in 
Dmp1-expressing cells results in protection from muscle-paralysis induced deterioration 
of trabecular bone structural parameters, most of which is not attributable to direct 
skeletal effects of tamoxifen treatment.   
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Figure 14. Mice with constitutive activation of β-catenin are not protected from 
mechanodeprivation-induced bone loss during 4 weeks of muscle paralysis disuse. 
Percent change in right tibial (A,C) bone mineral density and (B,D) content calculated 
from DEXA scans collected just prior to the start of the experiment and again at sacrifice 
following 4 weeks Botox in cat CA Cre-positive and Cre-negative mice. N=10/group 
Data were tested using 2-way ANOVA with Tamoxifen/oil and the Botox injection as 
main effects.  Inset at the top of each graph indicates significance of the main effects and 
interaction (#=Tamoxifen/Oil  p<0.05; @=Botox p<0.05; †=interaction p<0.05).  When 
at least one term was significant, Fisher’s PLSD post-hoc tests were conducted between 
saline and botox injected mice and are indicated as *p<0.05. 
D C 
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Gene Expression in Osteocyte-Enriched Lysates 
Differential gene expression analysis using RNAseq identified 396 genes up- and 222 
genes down-regulated in mice with stabilized ‐catenin following tail suspension 
compared to stabilized ‐catenin ground controls (Figure 16A).  Eighty-one genes were 
up- and 27 genes were down-regulated in tail-suspended uninduced mice compared to 
induced ground controls (Figure 16B). Sixty-nine of these genes including Calcr (up), 
Apod (up) and Ostn (down) were commonly changed in both stabilized ‐catenin  mice 
and non-stabilized mice in response to tail suspension (Figure 16). Thirty-five genes 
including Wnt11, Gli1, Nell1, Gdf5 and Pgf were significantly differentially regulated 
between tail-suspended -catenin stabilized mice and tail suspended non-stabilized mice 
(Figure 16C). Many of these genes were also differentially regulated between stabilized 
and non-stabilized ground controls (Figure 16C), suggesting that these genes are likely -
catenin targets. These genes might play a role in the -catenin-mediated osteoprotective 
effects of disuse-induced bone wasting.  
  Figure 16. RNAseq of  bones 
from βcatCA mice A) Number 
of genes up- and down-
regulated in tail suspended 
stabilized -catenin (cat CA) 
mice and uninduced (control) 
mice compared to respective 
ground controls. B) Number of 
genes up- and down-regulated 
in tail suspended cat CA mice 
compared to tail suspended 
uninduced mice. C) Heatmap 
showing the expression 
profiles of protein coding 
genes differentially expressed 
between tail suspended cat 
CA mice and tail suspended 
WT mice. N=3 
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Chapter 4: The R1170W mutation in Lrp4 increases bone mass via loss of facilitator 
function with sclerostin 
Mice with the Lrp4 R1170W mutation exhibit increased bone mass 
To better understand the cellular mechanisms driving the high bone mass (HBM) 
phenotype in SOST2 patients, I generated an orthogonal mouse model to one of the 
families (LRP4 R1170W) using a CRISPR/Cas9 approach (Figure 17A).  A C→T point 
mutation was knocked into the first position of the codon for aa.1170 (confirmed by 
Sanger sequencing, Figure 17B), which resulted in the predicted Arg→Trp amino acid 
substitution.  Western blotting for Lrp4 indicated that the missense mutation had no effect 
on protein expression in cortical bone (Figure 17C).  
Figure 17. Generation of Lrp4 R1170W knockin mouse model. A) Mouse Lrp4 genomic DNA 
schematic, showing the exon 25/intron 25 targeting area.  A CRISPR/Cas9 approach was used to 
replace a 135bp sequence with a donor oligo containing a C→T mutation at position 1 of aa1170, 
as well as two silent mutations in the flanking codons to facilitate genotyping.  B) PCR products 
from exon 25 were sequenced to confirm mutations. A representative Sanger electropherogram 
from a heterozygous knockin mouse shows equal expression of the 3 individual base substitutions 
in the three consecutive codons.  C) Western blot of cortical bone tissue protein extract from 6-8 
week old Lrp4 WT and Lrp4KI mice, immunoreacted for Lrp4 (~240kDa), indicating comparable 
Lrp4 protein expression levels in Lrp4KI vs. Lrp4 WT mice.  Lane loading equivalency was 
assessed by stripping and reprobing for the focal adhesion protein vinculin (lower panel) and via 
Ponceau-S staining of the membrane for total protein prior to blotting (right panel).     
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I next sought to determine whether the Lrp4-R1170W knockin male and female mice 
(hereafter referred to as Lrp4KI) recapitulate the skeletal phenotype reported for SOST2 
patients with centrally located 3rd β-propeller missense mutations (R1170W, R1170Q, 
W1186S).  The Lrp4KI colony was expanded, along with wild-type and heterozygous 
littermates, and subjected to a battery of skeletal phenotyping endpoints.  The mutation 
did not affect body mass or femur length, but Lrp4KI mice displayed significant increases 
in DXA-derived whole body bone mineral density (BMD) and content (BMC) as early as 
6 weeks of age (Figure 18A, Tables 1 and 2).  At 18 weeks of age, µCT-derived femur 
and vertebral cortical and cancellous bone mass were significantly increased in Lrp4KI as 
compared to both WT and heterozygous littermates (Figure 18D-G).  pQCT-derived 
cortical BMC and trabecular BMD in the proximal tibia of 8-week-old Lrp4KI mice were 
also significantly elevated (Figure 18H-J).  Three-point bending tests conducted on 
femora from 18 week old mice revealed improved biomechanical properties in Lrp4KI 
mice, including significantly increased ultimate force and energy absorption (Figure 18K-
M).  
Patients with SOST2 display calvarial sclerosis, which is recapitulated in Lrp4KI 
mice, though much more robustly in male mice compared to female mice (Figure 18N-P, 
Table 2).  It was previously reported that stenosis of cranial nerve foramina in the 
basicranium of Lrp5-HBM and Sost knockout mouse models [71], which, at least in 
sclerosteosis patients, can lead to cranial nerve deficits.  However, foramen ovale area 
was not significantly affected by the Lrp4KI mutation (Figure 18N-P). Although not 
reported in SOST2 patients, I also found dental anomalies in Lrp4KI mice, including 
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supernumerary incisors and molars, with altered cusp morphology (Figure 19).  In 
summary, Lrp4KI mice recapitulate the human HBM phenotype associated with SOST2.  
Lrp4KI mice have increased bone formation, sclerostin expression, and mildly 
impaired muscle function 
Understanding of the mechanism of action (increased osteoanabolism or decreased 
osteocatabolism) for the observed HBM phenotype in Lrp4KI mice can guide translational 
applications for Lrp4 targeting.  To address cellular activity, I performed quantitative 
cortical bone histomorphometry on Lrp4KI and WT control mice.  In skeletally mature 
(16-17 weeks of age) mice, mineralizing surface and bone formation rate were increased 
on the endocortical surface (Figure 20A-G). No changes in the resorption marker CTx 
were detected in 8 wk-old wild-type or Lrp4KI mice (Figure 21H). Taken together those 
observations suggest that the increased bone mass observed in Lrp4KI mice is due to 
increased bone formation, positioning Lrp4 as a target for anabolic action in bone.    
Lrp4 has been proposed to serve as a sequestering protein for sclerostin, where it 
might serve as a “molecular net” to keep sclerostin levels high in the perimembrane  
region of bone cells [83].  Serum levels of sclerostin were significantly greater in Lrp4KI 
mice than in WT and heterozygous mice (Figure 20I), which is consistent with patient 
data [1] and supports the premise that mutant Lrp4 has impaired ability to retain 
sclerostin at the cell surface.  However, cortical bone tissue lysates from Lrp4KI mice 
yielded greater levels of sclerostin than lysates from WT mice (Figure 20H), which runs 
counter to the proposal that osteocytes with mutant Lrp4 are less efficient at retaining 
sclerostin locally.   
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Lrp4 is critical for neuromuscular junction (NMJ) formation and muscle function, 
where it serves as a receptor for motoneuron-derived Agrin, triggering interaction with 
MuSK [84].  Mutations in the 3rd β-propeller of Lrp4 can affect Agrin and MuSK binding 
[85], so I performed in vivo muscle force testing in 8 week old female WT and Lrp4KI 
mice to determine whether muscle function was affected by the R1170W missense 
mutation.  Time to maximum torque and half relaxation time were not different between 
WT and Lrp4KI mice, but maximum torque was significantly lower in Lrp4KI mice 
(Figure 20J-M). However, a change in muscle function does not explain the HBM 
phenotype in Lrp4KI mice since the mutation was associated with reduced rather than 
enhanced muscle forces on the skeleton.  In summary, Lrp4KI mice have HBM due to 
increased anabolic activity, despite increased local and systemic sclerostin and 
compromised muscle function.       
 
Figure 19. Lrp4KI mice display 
supernumerary teeth and altered 
molar cusp patterns. Top panel: µCT 
reconstructions from the occlusal 
view of the maxillary incisors 
illustrating a set of secondary 
incisors (blue arrow) distolingual to 
the primary set in the Lrp4KI mice.  
Middle/lower panel: close-up view 
of the mandibular dentition reveal 
extra incisors of varying 
development, and additional molar 
teeth on the distal end and lingual 
edge of the tooth row (blue arrows).  
The molars also exhibit altered cusp 
pattern compared to those seen in the 
WT mice. 
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Figure 20. Lrp4KI mice have increased bone formation, increased circulating and local sclerostin, 
and reduced skeletal muscle function. A) Quantitative endocortical bone histomorphometry of the 
midshaft femur of 18 week old +/+, +/KI and KI/KI female mice, measured using labels injected 
at 8 (orange) and 11 (red) weeks of age (B-D), and again using labels injected at 16 (green) and 17 
(red) weeks of age (E-G), indicate a significant increase in the bone formation parameters 
mineralizing surface (MS/BS), mineral apposition rate (MAR), and bone formation rate (BFR/BS) 
at the later time point.  (H) Western blot of cortical bone tissue protein extract from 6-8 week old 
Lrp4 WT and Lrp4KI mice, immunoreacted for sclerostin (~30 kDa), indicating increased 
sclerostin protein expression levels in Lrp4KI vs. Lrp4 WT mice.  Lane loading equivalency was 
assessed by Ponceau-S staining of the membrane for total protein prior to blotting (right panel). (I) 
Serum sclerostin was also significantly elevated in the circulation of Lrp4 KI mice, compared to 
+/+ and +/KI mice.  (J) In vivo muscle function of the anterior compartment musculature (left 
panel) in 10-wk old female mice revealed a deficiency in maximum torque (K), but not the time to 
maximum torque (L) or half muscle relaxation time (M), among Lrp4KI mice, compared to WT 
mice.  For panels B-I, p<0.05 for comparison to +/+ mice, using one-way ANOVA followed by 
Fisher’s PLSD post hoc tests; for panels in K-M, *p<0.05 for comparison to +/+ mice by repeated 
measures ANOVA.  n=6/group (B-G); 3-8/group (H-I); and 9-10/group (K-M). 
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Overexpression of Sost in bone tissue causes osteopenia in WT but not Lrp4KI mice  
Some reports suggest that Lrp4 acts as a facilitator of sclerostin inhibition of Lrp5/6, a 
proposition that is supported by direct interaction between the Lrp4 3rd β-propeller and 
sclerostin, and by suppression of sclerostin-mediated Wnt inhibition by Lrp4 knockdown 
[1].  To determine whether compromise of the sclerostin–Lrp4 interaction can account for  
the HBM phenotype of Lrp4KI, I bred Lrp4KI mice with transgenic mice that 
overexpress human Sost in osteocytes (8kbDmp1‐hSost).  As expected, whole body 
BMD and BMC were decreased in Lrp4 WT mice overexpressing Sost, but Lrp4KI mice 
were unaffected by Sost overexpression (Figure 21A, Tables 3 and 4).  Lrp4KI mice were 
protected from the osteopenic effects of Sost overexpression in the cancellous 
compartment of both the femur and spine (Figure 21B-D), but the protective effects in the 
cortical compartment could not be evaluated because Lrp4 WT mice did not manifest a 
Sost transgene effect, when evaluated by microCT (Figure 21E) or bone formation 
parameters (Figure 21F,G,I).  The resorption marker CTx was not affected by the Sost 
transgene in either Lrp4 genotype (Figure 21H).  In summary, the otherwise bone-
suppressive effects of excessive sclerostin in bone were absent in Lrp4KI mice, 
suggesting that the R1170W mutation confers resistance to the inhibitory effects of 
sclerostin. 
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Table 1. Radiographic and biomechanical analysis of female Lrp4 WT, HET and KI mice 
 Wild-type 
(WT) 
R1170W/+ 
(HET) 
R1170W/R1170W 
(KI) 
Whole Body BMC (18 wk; g) 0.49 ± 0.1 0.47 ± 0.1 0.77 ± 0.1 
Body Weight (18 wk; g) 22.5 ± 1.3 22.1 ± 1.0 21.6 ± 2.2 
Femur length (mm) 15.2 ± 0.5 15.0 ± 0.2 15.3 ± 0.5 
Femur µCT    
Tb.N (1/mm) 2.16 ± 0.35 1.88 ± 0.30 * 2.84 ± 0.29 * 
Tb.Th (mm) 0.04 ± 0.01 0.04 ± 0.01 0.08 ± 0.01 * 
Tb.Sp (mm) 0.47 ± 0.08 0.55 ± 0.09 * 0.34 ± 0.05 * 
Tb.BMD (mg/cm3) 868 ± 40 879 ± 37 924 ± 34 * 
Tb.BMC (mg) 0.06 ± 0.12 0.02 ± 0.01 0.41 ± 0.18 * 
Ct.BMD (mg/cm3)  1.08 ± 0.02 1.08 ± 0.01 1.09 ± 0.01 * 
Ct.BMC (mg) 2.59 ± 0.42 2.60 ± 0.09 3.97 ± 0.70 * 
5th Lumbar µCT    
Tb.N (1/mm) 3.79 ± 0.8 3.69 ± 1.0 5.93 ± 1.1 * 
Tb.Th (mm) 0.05 ± 0.01 0.05 ± 0.01 0.08 ± 0.02 * 
Tb.Sp (mm) 0.26 ± 0.04 0.27 ± 0.05 0.17 ± .05 * 
Tb.BMD (mg/cm3) 871 ± 10 878 ± 15 871 ± 19 
Tb.BMC (mg) 0.28 ± 0.19 0.26 ± 0.14 0.79 ± 0.27 * 
Femur 3 point bending    
Stiffness (N/mm) 70.2 ± 12.2 67.9 ± 21.9 108.6 ± 2.6 * 
Energy to FU (mJ) 3.38 ± 1.3 4.10 ± 1.3 9.35 ± 1.6 * 
Energy to FF (mJ) 10.1 ± 2.6 9.6 ± 2.9 15.3 ± 4.7 * 
*p<0.05 for comparison to WT mice, using one-way ANOVA followed by Fisher’s 
PLSD post hoc tests. 
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Table 2. Radiographic and biomechanical analysis of male Lrp4 WT, HET and KI mice 
 Wild-type 
(WT) 
R1170W/+ 
(HET) 
R1170W/R1170W 
(KI) 
Whole Body BMD (18 wk; g/cm2) 70.1 ± 7.3 75.0 ± 8.0 91.6 ± 12.6* 
Whole Body BMC (18 wk; g) 0.54 ± 0.1 0.57 ± 0.1 0.76 ± 0.2* 
Body Weight (18 wk; g) 28.3 ± 0.8 27.68 ± 3.2 26.34 ± 2.2 
Femur length (mm) 15.4 ± 0.5 15.1 ± 0.2 15.2 ± 0.2 
Femur µCT    
Tb.BV/TV (unitless) 0.046 ± 0.02 0.046 ± 0.02 0.166 ± 0.05* 
Tb.N (1/mm) 3.193 ± 0.34 2.960 ± 0.27 3.722 ± 0.31* 
Tb.Th (mm) 0.05 ± 0.00 0.05 ± 0.01 0.07 ± 0.01* 
Tb.Sp (mm) 0.31 ± 0.03 0.34 ± 0.03 0.25 ± 0.03* 
Tb.BMD (mg/cm3) 887.3 ± 8.7 887.1 ± 21.6 901.5 ± 15.0* 
Tb.BMC (mg) 0.16 ± 0.10 0.17 ± 0.08 0.67 ± 0.23* 
Ct.BMD (mg/cm3)  1.06 ± 0.01 1.06 ± 0.00 1.07 ± 0.01* 
Ct.BMC (mg) 2.43 ± 0.23 2.57 ± 0.21 3.79 ± 0.28* 
Ct.Th (mm) 0.188 ± 0.01 0.195 ± 0.01 0.259 ± 0.02* 
5th Lumbar µCT    
Tb.BV/TV (unitless) 0.20 ± 0.03 0.18 ± 0.03 0.37 ± 0.15* 
Tb.N (1/mm) 4.75 ± 0.22 4.45 ± 0.23* 5.63 ± 1.15* 
Tb.Th (mm) 0.47 ± 0.01 0.048 ± 0.00 0.06 ± 0.02* 
Tb.Sp (mm) 0.20 ± 0.01 0.21 ± 0.013* 0.18 ± 0.06* 
Tb.BMD (mg/cm3) 881.7 ± 6.3 882.5 ± 9.5 870.9 ± 23.5 
Tb.BMC (mg) 0.342 ± 0.07 0.289 ± 0.07 0.586 ± 0.24* 
Femur 3 point bending    
Ultimate Force (N) 15.7 ± 2.9 16.9 ± 2.7 32.2 ± 4.4* 
Stiffness (N/mm) 56.9 ± 18.7 79.9 ± 20.8* 102.7 ± 51.2* 
Energy to FU (mJ) 4.94 ± 1.5 4.92 ± 1.2 11.96 ± 3.7* 
Energy to FF (mJ) 8.2 ± 2.8 11.7 ± 3.0* 16.6 ± 3.5 * 
Cranial Dimensions    
Skull Thickness (µm) 0.201 ± 0.08 ---- 0.295 ± 0.05 * 
Foramen Ovale Area (µm) 0.337 ± 0.18 ---- 0.273 ± 0.11 
*p<0.05 for comparison to WT mice, using one-way ANOVA followed by Fisher’s 
PLSD post hoc tests. 
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Inactivation of sclerostin elicits a blunted osteogenic effect in Lrp4KI mice 
In the previous section I evaluated the ability of Lrp4KI mice to maintain high bone mass 
in the presence of excessive sclerostin.  Next, I evaluated the opposite condition 
regarding the sclerostin–Lrp4 interaction, i.e., whether Lrp4KI mice can elicit a full 
anabolic response when sclerostin is inactivated pharmacologically.   Four weeks of 
treatment with sclerostin monoclonal antibody (Scl-mAb) increased whole body BMD 
significantly compared to saline treatment in both WT and Lrp4KI female mice, but the 
antibody-induced BMD gain exhibited by Lrp4KI mice was only about half of that 
exhibited by WT mice (Figure 22E).  Large gains in µCT-derived parameters (trabecular 
and cortical bone mass in the femur and spine) were measured among WT mice in 
response to Scl-mAb, but a blunted response (roughly a third to a half of WT gains) was 
observed in Lrp4KI mice (Figure 22A-D).  Scl-mAb treatment increased bone formation  
parameters significantly in WT mice but not in Lrp4KI mice (Figure 22F-H).  In 
summary, the strong anabolic effects of sclerostin neutralization were compromised or 
absent in Lrp4KI mice, likely due to the mutation having similar functional (i.e., 
redundant) effects as Sost inactivation.  
Lrp4KI mice are partially protected from disuse-induced bone wasting 
Bone is a highly mechanosensitive tissue, and previous studies highlight the importance 
of canonical Wnt signaling, particularly sclerostin, in this process. Mechanical disuse 
induces an increase in Sost expression, and Sost genetic deletion or sclerostin 
pharmacologic neutralization prevents disuse-induced bone loss [86].  Given the 
accumulating evidence that the Lrp4 R1170W mutation confers properties to bone tissue 
that are similar to sclerostin neutralization, I explored the role of Lrp4KI in response to  
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61 
disuse mechanotransduction.  Lrp4KI mice (12 wks of age) were subjected to 4 wks of 
unilateral mechanical disuse of the hindlimb using the Botulinum toxin-induced muscle 
paralysis model, and the degree of bone wasting was evaluated radiographically.  The 
paralyzed limb of WT mice lost ~10% BMC, but Lrp4KI mice did not lose BMC in 
response to Botox (Figure 23A).  However, while bone loss was spared in the paralyzed 
limb of Lrp4KI mice, I detected a significant failure to gain bone as was observed in the 
saline-treated limb of Lrp4KI mice (Figure 23A).  Proximal tibial trabecular bone mass 
was significantly reduced by Botox in both WT and Lrp4KI mice, but the Lrp4KI mice lost 
roughly half as much bone as WT mice in response to paralysis (Figure 23B-D).  Cortical 
bone loss was significant in Botox treated WT mice, but paralyzed limbs from Lrp4KI 
mice exhibited no difference from saline treated limbs.  In summary, Lrp4KI mice exhibit 
less severe bone wasting in response to mechanical disuse than WT mice, suggesting that 
pharmacologically targeting the 3rd -propeller of Lrp4 during a disuse event might have 
therapeutic value in reducing bone loss.  
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Figure 22. Response to pharmacologic inhibition of Sost is blunted in Lrp4KI mice. (A-C) 
Trabecular bone volume fraction (Tb.BV/TV) in the distal femur and 5th lumbar vertebra (L5), 
and cortical thickness (Ct.Th) in the mid-diaphyseal femur, were significantly increased in 16-wk 
old female Lrp4KI and WT (+/+) mice treated with sclerostin monoclonal antibody (Scl-mAb), 
but the gains were more pronounced in WT mice.  (D) µCT reconstructions from the midshaft 
femur (upper) distal femur (middle) and vertebral body (lower) from representative +/+ and 
KI/KI mice treated with vehicle (-) or Scl-mAb (+).  (E) Percent change in whole body bone 
mineral density (BMD) during the 4 week antibody treatment period was greater in WT mice 
compared to Lrp4KI mice.  (F-H) The periosteal bone formation parameters mineralizing surface 
(MS/BS), mineral apposition rate (MAR), and bone formation rate (BFR/BS) were significantly 
increased in WT but not Lrp4KI mice in response to sclerostin antibody. For all data panels, data 
were tested using 2-way ANOVA with Lrp4 genotype and the Scl-mAb injection as main effects.   
Inset at the top of each graph indicates significance of the main effects and interaction (#=Lrp4 
genotype p<0.05; @=Scl-mAb p<0.05; †=interaction p<0.05).  When at least one term was 
significant, Fisher’s PLSD post-hoc tests were conducted and are indicated as *p<0.05.  For all 
panels, n=6-10/group.  
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Figure 23. Lrp4KI mice are partially protected from disuse-induced bone loss. (A) Percent change 
in hindlimb bone mineral density (BMD) following 4 weeks of Botox-induced disuse. (B-C) 
Percent difference (side-to-side) in trabecular bone volume fraction (Tb.BV/TV) in the proximal 
tibia and cortical thickness (Ct.Th) in the mid-diaphyseal tibia, were significantly greater in 
Botox-treated WT mice compared to Botox-treated Lrp4KI mice. (D) µCT reconstructions at the 
proximal tibia from representative +/+ and KI/KI mice treated with Botox (+) or vehicle (-).  Data 
were tested using 2-way ANOVA using Lrp4 genotype and Botox injection as main effects.   Inset 
at the top of each graph indicates significance of the main effects and interaction (#=Lrp4 
genotype p<0.05; @=Botox effect p<0.05; †=interaction p<0.05).  When at least one term was 
significant, Fisher’s PLSD post-hoc tests were conducted and are indicated as *p<0.05.  For all 
panels, n=9-10/group. 
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Table 3. Radiographic analysis and serum measurements in WT and Lrp4-KI female 
mice with and without a Dmp1-hSost transgene 
 
WT / NTG WT / Dmp1-hSost KI / NTG 
KI / 
Dmp1-
hSost 
Whole Body BMC (17 
wk; g) 0.473 ± 0.02 0.446 ± 0.04* 0.610 ± .0.07 
0.639 ± 
0.09 
Femur µCT     
Tb.N (1/mm)#@ 2.11 ± 0.36 1.24 ± 0.46* 2.42 ± 0.39 1.99 ± 0.48 
Tb.Th (mm) # 0.038 ± 0.006 0.046 ± 0.013 0.067 ±0.010 
0.063 ± 
0.014 
Tb.Sp (mm) #@† 0.49 ± 0.10 0.88 ± 0.26* 0.41 ± 0.07 0.53 ± 0.15 
Tb.BMD (mg/cm3) # 923.7 ± 24.6 926.1 ± 31.7 948.9 ± 20.1 939.3 ± 18.2 
Tb.BMC (mg) #@ 0.05 ± 0.02 0.01 ± 0.01* 0.28 ± 0.14 0.17 ± 0.11 
Ct.BMD (mg/cm3) #  1.07 ± 0.01 1.06 ± 0.02 1.09 ± 0.02 1.08 ± 0.02 
Ct.BMC (mg) # 2.44 ± 0.14 2.35 ± 0.14 3.56 ± 0.34 3.54 ± 0.46 
5th Lumbar µCT     
Tb.N (1/mm) # 3.72 ± 0.2 2.41 ± 0.8 5.41 ± 2.5 5.13 ± 1.2 
Tb.Th (mm) # 0.048 ± 0.003 0.056 ± 0.007 
0.083 ± 
0.011 
0.085 ± 
0.021 
Tb.Sp (mm) #† 0.263 ± 0.16 0.440 ± 0.12* 0.254 ± 0.23 0.204 ± 0.06 
Tb.BMD (mg/cm3) # 849.6 ± 14.1 863.1 ± 29.0 875.5 ± 3.83 877.9 ± 23.6 
Tb.BMC (mg) # 0.237 ± 0.02 0.133 ± 0.06 0.617 ± 0.36 0.703 ± 0.27 
Serum sclerostin (pg/µL) 
# 148.3 ± 19 131.2 ± 32 700.3 ± 291 
778.8 ± 
335 
Symbols indicate significance of the main effects and interaction (#=Lrp4 genotype 
p<0.05; @=Dmp1-hSost p<0.05; †=interaction p<0.05).  When at least one term was 
significant, Fisher’s PLSD post-hoc tests were conducted and are indicated as *p<0.05. 
.  
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Table 4. Radiographic analysis and serum measurements in WT and Lrp4-KI male mice 
with and without a Dmp1-hSost transgene 
 WT / NTG WT / Dmp1-hSost KI / NTG 
KI / Dmp1-
hSost 
Whole Body BMC (17 wk; g) 0.55 ± 0.10 0.55 ± 0.10 0.68 ± 0.08 0.72 ± 0.13 
Whole Body BMD (17 wk; 
g/cm2) 72.3 ± 8.6 73.2 ± 8.6 85.1 ± 7.3 89.9 ± 10.2 
Femur µCT     
Tb.BV/TV (unitless) #† 0.08 ±0.04 0.05 ± 0.02* 0.12 ± 0.03 0.17 ± 0.04* 
Tb.N (1/mm) #@† 3.34 ± 0.68 1.98 ± 0.25* 3.32 ± 0.27 3.56 ± 0.32 
Tb.Th (mm) #@ 0.050 ± 0.01 0.058 ± 0.01* 0.067 ± 0.00 0.072 ± 0.00 
Tb.Sp (mm) #@† 0.307 ± 0.06 0.514 ± 0.06* 0.287 ± 0.03 0.266 ± 0.03 
Tb.BMD (mg/cm3) #† 916.5 ± 19.6 925.0 ± 19.1* 925.9 ± 9.8 936.1 ± 14.7* 
Tb.BMC (mg) #† 0.345 ± 0.19 0.184 ± 0.10 0.471 ± 0.13 0.793 ± 0.32* 
Ct.BMD (mg/cm3) #  1.05 ± 0.03 1.04 ± 0.03 1.07 ± 0.01 1.08 ± 0.02 
Ct.BMC (mg) # 2.58 ± 0.51 2.53 ± 0.19 3.47 ± 0.17 3.84 ± 0.47 
Ct.Th (mm) # 0.198 ± 0.03 0.198 ± 0.01 0.243 ± 0.01 0.244 ± 0.03 
5th Lumbar µCT     
Tb.BT/TV (unitless) #@ 0.24 ± 0.09 0.08 ± 0.01* 0.43 ± 0.05 0.40 ± 0.14 
Tb.N (1/mm) #@† 4.99 ± 0.5 2.09 ± 0.3* 6.37 ± 0.7 5.29 ± 1.4 
Tb.Th (mm) # 0.051 ± 0.01 0.060 ± 0.01 0.072 ± 0.00 0.078 ± 0.01 
Tb.Sp (mm) #@† 0.190 ± 0.02 0.479 ± 0.07* 0.141 ± 0.03 0.198 ± 0.11 
Tb.BMD (mg/cm3) 874.5 ± 14.1 871.7 ± 11.3 856.4 ± 8.0 870.2 ± 17.3 
Tb.BMC (mg) #† 0.40 ± 0.16 0.13 ± 0.03* 0.58 ± 0.02 0.59 ± 0.22 
Serum sclerostin (pg/µL) # 143.3 ± 37 121.6 ± 23* 1007 ± 173 993.4 ± 109 
Symbols indicate significance of the main effects and interaction (#=Lrp4 genotype 
p<0.05; @=Dmp1-hSost p<0.05; †=interaction p<0.05).  When at least one term was 
significant, Fisher’s PLSD post-hoc tests were conducted and are indicated as *p<0.05 
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Chapter 5: Discussion 
While the importance of Wnt signaling in bone is clear, our current understanding 
of this pathway in bone cell mechanotransduction has been largely focused on the Wnt 
co-receptor Lrp5 and the soluble inhibitor Sost. However, numerous other Wnt pathway 
components are involved in the response to mechanical stimuli in bone, but our 
understanding of these other molecules is somewhat limited. Here, I explore the role of β-
catenin in osteocytes in the context of a disuse environment. In addition, I define the role  
a less well-known Wnt signaling modulator—Lrp4.   
Regulation of β-catenin in osteocytes is necessary for mechanotransduction in disuse 
The downstream Wnt signaling modulator β-catenin has been explored in animal models 
of enhanced loading, where it was found to be necessary for load-induced bone formation 
[58, 59]. Activation of the Wnt signaling pathway results in the accumulation of β-
catenin. Conversely, β-catenin is degraded in the absence of mechanical signal, such as in 
musculoskeletal disuse. β-catenin is involved in the regulation of adherins junctions at the 
cell-cell contact points , and it also functions as a binding partner for specific 
transcription factors in the nucleus. Whereas this study does not distinguish between the 
different actions of β-catenin in the cell (i.e., cell membrane versus nucleas), it does 
emphasize the necessity of β-catenin in regulating the response of osteocytes to 
mechanotransduction, particularly in reduced mechanical stimuli environments. Here, I 
employed a mouse model in which β-catenin was constitutively and inducibly activated 
in osteocytes, and subjected mice to two different methods of disuse. In both models, 
constitutive activation of β-catenin resulted in some degree of protection from disuse-
induced bone loss, suggesting β-catenin regulation is critical for mechanotransduction in 
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bone. The Dmp1-Cre:ERt2 promoter, like all mouse models, is imperfect. While Dmp1-
Cre:ERt2 was engineered to target osteocytes, other cell types expressing low levels of 
Dmp1 are also activated by tamoxifen. Additionally, the recombination efficiency of 
Dmp1-Cre:ERt2 is low (10-15% recombination in boht the βcatCa and flox loss-of-
function alleles, see Chapter 3). While this leaves a large number of cells with intact β-
catenin activity, the resulting recombination efficieny was enough to elicit a protective 
effect in bone. Finally, one of the largest drawbacks of using the Dmp1-Cre:ERt2 driver 
is the utilization of tamoxifen to activate the Cre recombinase. The Cre:ERt2 transgene 
codes for a Cre fusion protein that remains cytosolic until the tamoxifen ligand 
encountered, which induces translocation to the nucleus where the Cre recombinase 
activity can have its effect on LoxP sites.  The direct effects of tamoxifen in bone are well 
known [87, 88]; therefore extensive control experiments were included in the design to 
account for the anabolic/anti-catabolic effects of tamoxifen in bone. In this study, I 
balanced tamoxifen administration to activate Cre recombinase activity while also 
minimizing the anabolic effects of tamoxifen in bone. To this end, additional controls 
were included to account for the tamoxifen effect in bone. Although treatment with 
tamoxifen increased bone mass in both Cre-positive and Cre-negative mice, the presence 
of tamoxifen alone (Cre-negative, disuse treated mice) offered no measureable protection 
against the bone wasting effects of either disuse model.  Those control experiments 
suggest that the skeletal rescue seen in Cre-positive, tamoxifen treated mice subjected to 
disuse were the result of -catenin activation rather than tamoxifen.  Additionally, the 
increase in bone parameters following tamoxifen administration alone (i.e., in ground 
control mice) appears to be similar in both Cre-positive and Cre-negative mice, though 
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this result was inconsistent (e.g., tibial BMC exhibited additional increases beyond the 
tamoxifen effect in Cre-positive ground mice), suggesting little additional benefit of βcat 
CA activation beyond the increases induced by tamoxifen. Although that effect was 
inconsistent (e.g., tibial BMC exhibited additional increases beyond the tamoxifen effect 
in Cre-positive ground mice), at least for some endpoints, βcat CA activation can have 
negligible effects that are only manifest when challenged by a disuse stimulus. 
As part of this study, I also performed high-throughput RNA sequencing on 
osteocyte-enriched hindlimb bone lysates from tail suspended mice.  The aim for those 
studies was geared toward hypothesis generation, to determine whether there were 
candidate genes or pathways that were associated with the protective effects of -catenin 
activation on disuse induced bone loss that might serve as better targets for skeletal 
therapies in disuse.   Those mice were sacrificed after 4 days to capture more acute 
changes in gene expression.  I found a number of genes that were significantly 
upregulated in activated tail suspended mice that were either not affected or 
downregulated in the uninduced suspended controls. I are currently pursuing some of 
these candidates to understand their potential role in protection from disuse osteopenia as 
part of the Wnt signaling pathway. GO pathway analysis of altered gene activity 
indicated in Gli1, Nell1 and Wnt11, which are all associated with Wnt signaling and 
osteoblast regulation.      
 The bone-wasting effects of disuse have been well characterized, and are 
commonly associated with clinical conditions such as prolonged bedrest, spinal cord 
injury, muscle paralysis, and immobilization (casting), among others.  Treatments for 
disuse-induced bone loss are limited.  The importance of canonical Wnt signaling in the 
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response of osteocytes to altered mechanical environments prompted us to investigate 
whether manipulating -catenin during disuse might have therapeutic potential for 
skeletal preservation.  I focused on an adult onset mouse model of -catenin constitutive 
activation (CA) in osteocytes, in conjunction with two disuse-associated 
mechanotransduction models, to address the efficacy of -catenin activation in 
preventing bone loss.  I consistently found that while uninduced mice subjected to disuse 
lost bone mass as expected, mice with induction of β-cat CA were protected from the 
bone wasting effects of disuse.  
 Both the fluid shift (tail suspension) and muscle paralysis (Botox) models of 
disuse support the conclusion that that induction of -catenin mitigates the bone wasting 
effects during disuse. Both models of disuse used here have benefits and limitations; tail 
suspension prevents regular locomotion within the cage, but muscle forces from kicking 
may still exert small forces on the bones. Additionally, stress hormones are increased in 
mice during tail suspension, and may have negative impacts on bone mass. Another 
consideration of this model is the shift in fluid to the forelimbs and head of the body 
during suspension.  Conversely, muscle paralysis does not completely prevent loading in 
the treated hindlimb. Muscle atrophy was reduced in these experiments, but muscle 
function was not completely abolished following botulinum toxin A (Botox) 
administration. In addition, many of these measurements do not account for the systemic 
effects Botox may have on the contralateral limb, or the bone gain that may occur in 
response to locomotive compensation in the contralateral limb. Due to either the sex-
dependent differences in response to disuse or the differences within each model system, 
I did note some differences in the responses to each model. The rescue effect of inducing 
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-cat CA during disuse was stronger in the tail suspension than in the Botox experiment 
when evaluated based on the DXA result (which is largely a cortical bone measurement).  
For example, Botox-induced bone loss (hindlimb BMD) was not statistically different 
between induced and uninduced mice (though the former was not different from controls 
whereas the latter was).  However, when evaluated based on the µCT results (a trabecular 
compartment measurement), both models yielded roughly equal efficacy of the -cat CA 
rescue effect.   Thus, -catenin activation might be a better strategy for preserving whole 
bone properties (cortical and trabecular) in disuse conditions involving fluid shift than for 
paralysis-based disuse, where cortical bone might be more susceptible to loss.  
 The results of the β-catenin study indicate that -catenin is a key regulator of the 
bone-wasting response in a disuse mechanical environment, matching similar findings in 
studies of other key Wnt signaling molecules in disuse. Mice with gain of function 
missense mutations in Lrp5 are protected from disuse-induced bone wasting [71], as are 
as mice with deletion of the Wnt inhibitor Sost [86, 89].  Additionally, pharmacological 
neutralization of Sost prevents bone wasting during disuse [90]. Targeting of the Wnt 
signaling pathway as a therapy for osteoporosis and other bone diseases has been 
explored, with the use of Sost antibody as a potential therapeutic target.  Lithium chloride 
(LiCl) is a clinically approved treatment for depression, schizophrenia, bipolar disorder, 
and other mood disorders.  LiCl inhibits GSK3, a major component of the -catenin 
degradation complex [91], which is responsible for phosphorylating  -catenin at serine-
threonine residues in exon 3.  Thus, while LiCl is probably an inappropriate choice for 
patients subjected to disuse (due to side effects), epidemiological analysis of patients 
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taking LiCl for other reasons, who happen to also encounter a disuse event, might reveal 
the translational capacity of β-catenin activation for preserving bone mass.    
 -catenin is responsible for multiple modes of regulation in osteocytes, and 
constitutive activation of -catenin in this study does not distinguish between these 
pathways. -catenin is involved in modulating the mechanotransduction response through 
its functions at the plasma membrane via cell-cell junctions, gap junctions and in the 
nucleus as a transcription factor and regulator of multiple gene expression pathways. 
Increased -catenin accumulation by constitutive activation of -catenin likely increases 
both membrane and nuclear accumulation of -catenin, although changes in cellular 
distribution of β-catenin following constitutive activation have not been defined. 
Additional non-canonical effects of Wnt/B-catenin signaling in bone cannot be ruled out 
[92]. The RNAseq results provided here will provide further insight into the 
regulatory/gene transcription role of -catenin in response to disuse.   
  The β-catenin study had several limitations that should be acknowledged.  First, 
tamoxifen is not the ideal choice for a chemical inducer of Cre activity, as discussed 
earlier, due to its direct effects on bone metabolism.  Our aim was to start the disuse 
experiments in adult mice that had a relatively normal skeleton (i.e., avoid a constitutive 
Cre that might generate an HBM phenotype before the disuse experiment was initiated).  
There are limited choices for adult-onset (inducible) Cre induction in osteocytes.  I did a 
battery of additional experiments to account for the increases in bone mass following 
treatment with tamoxifen, but there might be other effects of tamoxifen that I could not 
resolve.  Another limitation of the study was the use of a single sex for each disuse 
treatment (females for disuse, males for Botox). This study design was chosen due to the 
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high number of mice required for each experiment (including all the tamoxifen controls) 
as well as animal welfare concerns. Previous disuse studies have found no sex-dependent 
differences in response to disuse, suggesting that use of a single sex for each stimulus 
probably has little effect on the general conclusions. Third, these studies cannot 
distinguish between the nuclear role and the plasma membrane role of -catenin.  -
catenin plays a very important role in modulating cell mechanics via its function at cell–
cell junctions, where it interacts with p120 catenin, vinculin, and the actin cytoskeleton, 
among other structural proteins. -catenin regulates expression of Cx43 and gap junction 
formation between osteocytes [93], and is also critical for mediating transcription of Wnt 
target genes in the nucleus, via its interaction with Tcf and Lef1 transcription factors.  
Constitutive activation of -catenin would presumably have effects on protein longevity 
and function at both sites, but the relative contribution of these loci cannot be addressed 
by the current experiments.   
 In conclusion, these findings indicate that targeting/blocking of -catenin 
degradation in bone cells could have therapeutic implications in mechanically induced 
bone disease.  The advancement of nanotechnology has made organ targeting of 
compounds more precise and effective, and the potential to target -catenin selectively in 
bone might be a viable approach to preserving bone mass during disuse.  More broadly, 
this data support the crucial role of Wnt signaling in bone metabolism, and highlight the 
therapeutic value of manipulating a downstream node in the canonical pathway to 
improve skeletal disease. 
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Lrp4 mediates bone homeostasis and mechanotransduction through Sost 
While the role of the soluble inhibitor Sost in Wnt signaling has been explored 
extensively, the role of the novel Sost facilitator in bone, Lrp4, is less clear. Here, I 
generated a mouse model to mimic the high bone mass phenotype observed in SOST2 
patients using Crispr/Cas9 to generate the R1170W point mutation. As seen in patients, 
mice with the Lrp4 R1170W mutation exhibited high bone mass and dramatic increases 
in circulating sclerostin levels. Additionally, I were able to utilize this mouse to evaluate 
the role of Lrp4 in ways that cannot be measured in human patients, including muscle 
function, bone formation and the effect of treatments in the presence of altered Lrp4. I 
found that that Lrp4 is necessary for Sost inhibition even when sclerostin is highly 
overexpressed. Additionally, altered Lrp4 has partial effects on both the response to 
sclerostin antibody as well as disuse in mice.  
 Understanding the role of individual molecules in Wnt signaling is critical for 
treatment of low bone mass and bone disease. While numerous therapeutics exist for 
treatment of low bone mass, most of them are driven towards preventing further bone 
loss, rather than building new bone. In addition, each of the established bone therapies is 
associated with side effects ranging from cardiovascular events to increased cancer risk. 
The recent FDA approval of romosozomab marks the first anabolic bone therapy on the 
market, but also has a black-box label due to associated side effects. The work shown 
here provides potential insight into novel therapeutic targets or concurrent therapies to 
enhance available drugs.  
High bone mass (HBM)-causing mutations in genes coding for secreted or plasma 
membrane-bound Wnt signaling components represent rare glimpses into molecular 
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targeting opportunities to improve bone health and fracture resistance in osteoporotic 
patients.  Targets that can be modulated to produce anabolic action in the skeleton are 
particularly attractive, given the paucity of approved and pipeline osteoanabolic agents.  
The identification of sclerosteosis-like patients harboring missense mutations in LRP4 [1] 
has furthered our understanding of accessory proteins involved in extracellular Wnt 
inhibition, and also provided additional avenues for therapeutic development.  I 
engineered an orthologous mouse model to one of the HBM human families identified 
with an HBM-causing LRP4 missense mutation, which yielded an HBM phenotype and 
provided a tool to study more mechanistic questions beyond those suited to clinical 
studies (e.g., bone strength, tissue protein levels).  I found that the Lrp4 R1170W knockin 
mice recapitulate the skeletal phenotype observed in SOST2 patients, and that the 
phenotype is driven largely by anabolic action.   
Moreover, I were able to identify several additional traits associated with Lrp4 
3βCD mutation that have not been reported in SOST2 patients, including changes to the 
dentition (also observed in other Lrp4 models [94], compromised muscle function, and 
increased levels of sclerostin in osteocyte-enriched protein lysates from bone tissue.  
Conversely, I failed to find some traits in the murine model that have been identified in 
patients (e.g., skull thickness, phenotype in the heterozygous state). The reduction in 
muscle function in Lrp4KI mice is surprising.  Certain missense mutations in the 3rd β-
propeller of LRP4 (e.g., E1233K and R1277H) can cause congenital myasthenic 
syndrome (CMS), a non-autoimmune disorder associated with progressive muscle 
weakness.  CMS mutations located on the outer edge of the 3rd β-propeller impair Lrp4 
interaction with both Agrin and MuSK—key interactions for neuromuscular junction 
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assembly and maintenance [85].  However, cell culture models show that overexpression 
of R1170W impairs Wnt signaling but has no effect on Agrin-induced MuSK signaling, 
suggesting that centrally located missense mutations (e.g. R1170W) affect Wnt but not 
Agrin/MuSK, whereas those located on the propeller edge have the inverse effect.  These 
data do not identify a direct role for the R1170W mutation in regulating muscle function; 
other indirect explanations (e.g., R1170W-induced increase in circulating sclerostin 
might impair muscle function) cannot be ruled out.  
Another interesting finding was the increased levels of sclerostin protein in bone 
extracts.  Human LRP4 HBM patients [83], other mouse models of Lrp4 mutation [62, 
95], and WT mice treated with Lrp4 neutralizing antibody [63] all have increased levels 
of circulating sclerostin, which I confirmed in my R1170W model.  Additionally, I also 
found increased sclerostin protein in bone, which was surprising given (1) Lrp4’s 
purported role in retaining sclerostin at high levels in the local bone environment (which 
is presumably inhibited by the Lrp4 HBM mutations), and (2) previous reports of 
decreased sclerostin in the osteocytes of Lrp4 knockin mice (R1170Q), as assessed by 
immunohistochemistry [95].  One explanation for the increase in tissue sclerostin despite 
a lack of its primary retention mechanism (functional Lrp4) that is consistent with 
previous data is the self-regulation of sclerostin expression observed when sclerostin 
signaling is inhibited genetically or pharmacologically [96].   
Investigation of the interaction between Lrp4 and sclerostin has thus far been 
restricted to cell culture experiments involving overexpression of various signaling 
components, which have the potential to be problematic or misleading specifically in 
Wnt-related in vitro studies [97].  I designed in vivo experiments to better understand this 
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interaction in a more physiologic context, and did so using excessive (hSost transgene) 
and depleted (Scl-Ab) sclerostin levels in Lrp4KI mice.  Lrp4KI mice were largely immune 
to changes in levels of sclerostin, where Lrp4KI mice overexpressing Sost failed to 
manifest the osteopenic effects of the transgene, and antibody-treated Lrp4KI failed to 
gain as much bone as treated WT mice (though they did exhibit significant gains for 
several parameters).  Whereas those experiments do not prove a direct role in binding 
alterations, they do suggest that Lrp4 3βCD mutations disturb the normal function of 
sclerostin in regulating bone mass in an in vivo context, both positively and negatively.    
To provide a translational context to Lrp4 clinical utility, I explored the role of 
Lrp4 in mediating disuse osteoporosis.  Wnt is a major regulator of mechanical signaling 
in bone, and I have previously reported therapeutic effects of modulating Lrp5, Sost, and 
β-catenin in mechanical models [71, 86, 98].  Here, I evaluated the utility of Lrp4 
modulation in a muscle paralysis model of bone loss.  Lrp4KI mice exhibited significant 
protection from the bone wasting effects of lower limb paralysis, suggesting that 
pharmacologic targeting of Lrp4 during or soon after a disuse injury might have clinical 
benefit. 
Future directions 
Gaining an improved understanding of the role of Wnt signaling proteins in the 
regulation of bone in response to mechanical environment has the potential to develop 
novel therapeutics for low bone mass diseases, as well as increase our understanding of 
the function of these pathways in overall bone maintenance and health. The work shown 
here provides many different pathways to explore future targets, bone therapies and 
unanswered questions. In the model in which degradation-resistant β-catenin mice were 
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subjected to disuse, this work suggests disruption of normal β-catenin regulation protects 
bone during disuse. Future work will be done to characterize the novel targets discovered 
here critical for the β-catenin mediated response to mechanical deprivation in osteocytes.  
One key area for future work is further characterization of Lrp4. Here, I have 
demonstrated the critical role for a key component of Lrp4 in Sost facilitator function, 
which has been hypothesized based on cell culture expriments, but not tested in vivo to 
date. Further characterization of Lrp4-Sost facilitator function are currently underway via 
fluorescent resonance energy transfer (FRET) studies. Here, I are exploring the direct 
interaction of Lrp4, Lrp5 and sclerostin in the presence of normal (wild-type) Lrp4 and 
R1170W Lrp4. The R1170W Lrp4 mice are also being utilized to explore the muscle 
phenotype identified in these studies, but not characterized further here. The generation 
and characterization of a bone-specific deletion of Lrp4 (Prx1-Cre;Lrp4flox/flox) is 
ongoing. This mouse model will differ from the R1170W Lrp4 mutant mouse in two key 
ways. Firstly, this will be a bone-specific deletion of Lrp4 instead of a global knock-in 
mutation, limiting the effects of other tissues (such as muscle). This will improve our 
understanding of Lrp4 function in bone specifically, rather than global alteration of Lrp4 
and the role of the specific 3rd beta-propeller central domain and its role in Sost function. 
Secondly, this bone-specific deletion model will effect not only Sost function, but also 
other Wnt inhibitors interacting with Lrp4 in bone and will disrupt Agrin-MuSK 
signaling in bone, which presents another possible avenue of exploration in the Lrp4 
signaling mechanisms in bone. Because Lrp4 is also critical in CMS, understanding the 
effects of this disease in bone will broaden the scope of this work.  
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Finally, the overall aim of this work is to identify potential targets for therapeutic 
treatments in low bone mass disease. The β-catenin study presented here provides proof-
of-concept for targeting intracellular Wnt signaling nodes for treating low bone mass 
disease, particularly in the context of bedrest or microgravity-induced bone wasting. 
While β-catenin has not previously been ideal as a therapeutic target due to the 
importance of β-catenin in other tissues as well as cancer, technological advances in 
tissue-specific drug targeting make the possibilities of utilizing β-catenin, or downstream 
targets of β-catenin a possibility in the future. Given the dramatic rescue effect of β-
catenin (strong protective effects despite low recombination rates), B-catenin would be an 
ideal target for low bone mass disease treatment when targeted drug treatment becomes a 
reality. 
Targeting of Lrp4 perhaps provides a more tenable focus for low bone mass 
therapies. While Lrp4 is globally expressed, and critical in NMJs formation, I have 
identified a critical role of the 3rd beta-propeller central domain in bone specifically. 
Future work is aimed at identification of pharmacological targeting of Lrp4 via either 
antibody treatment (currently being explored) or small molecule-targeting of the 3rd beta-
propeller central domain.  
Previous work, as well as the work shown here, identifies Wnt signaling as an 
ideal target for low bone mass therapies. This is demonstrated by the recent regulatory 
approval for clinical use of sclerostin-neutralizing antibody in several countries (US, 
Japan, Canada, South Korea, Australia), and has opened the door for widespread use of 
the first Wnt-based therapy for bone health. Whether other components (e.g., Lrp4) alone 
or in conjunction with sclerostin targeting can provide additional benefits to patients 
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remains to be determined, but Lrp4 targeting for low bone mass states appears attractive 
from a preclinical perspective. Advances in drug delivery technology may soon provide 
tissue-specific targeting strategies for therapies once considered unusable due to systemic 
effects, including -catenin. 
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